Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance

Karen A. Boehme 1,*, Sabine B. Schleicher 2, Frank Traub 3 and Bernd Rolauffs 1

1 G.E.R.N. Tissue Replacement, Regeneration & Neogenesis, Department of Orthopedics and Trauma Surgery, Medical Center—Albert-Ludwigs-University of Freiburg, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, 79108 Freiburg, Germany; berndrolauffs@googlemail.com
2 Department of Hematology and Oncology, Eberhard Karls University Tuebingen, Children’s Hospital, 72076 Tuebingen, Germany; sabine.schleicher@med.uni-tuebingen.de
3 Department of Orthopedic Surgery, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany; frank.traub@med.uni-tuebingen.de

* Correspondence: karen.boehme@web.de; Tel.: +49-176-51505012

Received: 16 December 2017; Accepted: 18 January 2018; Published: 21 January 2018

Abstract: Unlike other malignant bone tumors including osteosarcomas and Ewing sarcomas with a peak incidence in adolescents and young adults, conventional and dedifferentiated chondrosarcomas mainly affect people in the 4th to 7th decade of life. To date, the cell type of chondrosarcoma origin is not clearly defined. However, it seems that mesenchymal stem and progenitor cells (MSPC) in the bone marrow facing a pro-proliferative as well as predominantly chondrogenic differentiation milieu, as is implicated in early stage osteoarthritis (OA) at that age, are the source of chondrosarcoma genesis. But how can MSPC become malignant? Indeed, only one person in 1,000,000 will develop a chondrosarcoma, whereas the incidence of OA is a thousandfold higher. This means a rare coincidence of factors allowing escape from senescence and apoptosis together with induction of angiogenesis and migration is needed to generate a chondrosarcoma. At early stages, chondrosarcomas are still assumed to be an intermediate type of tumor which rarely metastasizes. Unfortunately, advanced stages show a pronounced resistance both against chemo- and radiation-therapy and frequently metastasize.

In this review, we elucidate signaling pathways involved in the genesis and therapeutic resistance of chondrosarcomas with a focus on MSPC compared to signaling in articular cartilage (AC).

Keywords: chondrosarcoma; articular cartilage; mesenchymal stem and progenitor cell; primary cilia; angiogenesis; metastasis; differentiation; fibroblast growth factor 2; isocitrate dehydrogenase; vascular endothelial growth factor

1. Chondrosarcoma Subtypes and Epidemiology

Chondrosarcomas are rare mesenchymal tumors with a cartilage-like appearance. They account for 10–20% of all malignant bone tumors [1]. In Europe, the incidence of chondrosarcoma is 0.1:100,000 [2]. In comparison, the incidence of osteoarthritis (OA) is 100–200:100,000, with a prevalence of symptomatic OA of about 20% in people aged ≥50 years [3,4].

Indeed, the term chondrosarcoma encompasses a group of tumors, which are heterogeneous both morphologically and clinically. About 80–90% of all chondrosarcomas are conventional chondrosarcomas [5]. Conventional chondrosarcomas start to grow intramedullary (central) and often affect the pelvis, femur and humerus, but also ribs and ilium [6]. The highly aggressive dedifferentiated chondrosarcomas, which make up about 10% of all chondrosarcomas [7] most often arise in the long
bones, namely the femur and humerus or the pelvis [8]. Dedifferentiated chondrosarcomas consist of chondroid and non-chondroid parts often resembling fibroblastic or osteoblastic tissue indicating two types of mesenchymal differentiation in one tumor [9,10]. Notably, the non-cartilaginous part of these tumors seems to determine local growth and recurrence [11].

Secondary chondrosarcomas may develop from formerly benign central cartilage lesions like enchondromas [12]. In addition, peripheral chondrosarcomas may arise from the cartilaginous cap of osteochondromas, which are benign bone tumors of childhood and adolescence [13,14]. Moreover, there are very rare low-grade entities like clear cell chondrosarcomas, which often involve the epiphysis of the proximal femur and humerus and extend to the articular cartilage (AC) of the acetabulofemoral joint and glenohumeral joint [15,16].

Unlike other bone sarcomas, conventional and dedifferentiated chondrosarcomas have their peak incidence at the ages of 40–70 years [8,17]. In contrast, clear cell chondrosarcomas and peripheral chondrosarcomas more often affect adolescents and young adults [15].

Low grade chondrosarcomas rarely metastasize. In the 2013 World Health Organization (WHO) classification system, grade I chondrosarcomas have been renamed as atypical cartilaginous tumors describing their clinical behavior as an intermediate type of tumor [1,18,19]. In contrast, high grade chondrosarcomas, which make up 5–10% of all conventional chondrosarcomas, are very aggressive and frequently metastasize to the lung [5] with a five-year survival rate of 50–60% and a ten-year survival rate of only 30–40% [6]. Yet, also about 20% of low grade tumors locally recur [6].

2. Mesenchymal Stem and Progenitor Cells in Adult Bone and Cartilage

Mesenchymal stem and progenitor cells (MSPC) exhibiting multipotent differentiation potential are resident in the bone marrow [20]. Although, the cells of origin of chondrosarcoma are still not clearly defined [21,22], conventional and dedifferentiated chondrosarcomas most likely develop from MSPC in the medullary space of bones [23].

According to the International Society for Cellular Therapy (ISCT), bone marrow derived mesenchymal stem cells (MSC) must differentiate to osteoblasts, adipocytes and chondrocytes in vitro and should at least express the markers cluster of differentiation 73 (CD73), CD90 and CD105, while markers characteristic for monocytes (CD11b or CD14), B cells (CD19 or CD79a), hematopoietic stem cells (HSC) (CD34), leukocytes (CD45 or human leukocyte antigen—antigen D related (HLA-DR)) are absent [20,24]. In addition, stromal cell surface marker-1 (STRO-1) and CD106 positive MSPC have a high proliferative potential [25]. Indeed, MSPC express a mixture of markers which undergo dynamic changes according to growth factor and cytokine availability during development and disease or artificial plastic adherence in cell culture [26,27]. In addition, MSPC marker expression depends on the species [27].

Actually, chondrosarcomas express several proteins either known as MSPC markers, chondrogenic markers or markers of other mesenchymal lineage commitment (Figure 1). From primary conventional chondrosarcomas, two cell types with different marker expression signatures have been isolated. One group resembled multipotent MSC (CD49b high/CD10 low/CD221, also known as insulin-like growth factor 1 receptor (IGF1R), high), whereas a second group more likely corresponded to a fibroblastic lineage (CD49b low/CD10 high/CD221 low). This implicates that both chondrosarcoma cell types arose from MSC, which are the assumed origin of chondrosarcomas [23].

CD44, also known as phagocytic glycoprotein 1 (PGP-1) is a tumor stem cell marker and receptor for hyaluronan, osteopontin (OPN), collagens, and matrix metalloproteinases (MMP) in various tissues (Figure 2). Moreover, CD44 may act as a cofactor for vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2) binding. After cleavage, its intracellular domain is involved in transactivation of notch homolog 1 (NOTCH1), receptor activator of NF-κB ligand (RANKL) and MMP-9 expression [28]. CD44 overexpression is increased in chondrosarcomas with progressive grading and correlated with metastatic potential and survival [29]. Interestingly, CD44 expression in human MSPC seems to be acquired in culture since freshly isolated MSPC are generally negative for this marker [30,31]. CD271, a stem cell marker, which may be associated with osteogenic potential
of MSPC [32], was expressed by a highly proliferative subpopulation of chondrosarcoma cells [33], indicating that sustained stemness may increase chondrosarcoma proliferation.

Members of the SRY-related HMG box-containing (SOX) family of transcription factors are master regulators of cell differentiation [34,35]. Human conventional chondrosarcomas of all grades express SOX9 [36], which is the main mediator of chondrogenesis [34]. In addition, SOX5 and SOX6 augment the pro-chondrogenic transcriptional activity of SOX9 [37]. MiR-145, which negatively regulates SOX9, was downregulated in human chondrosarcomas, enhancing the relative abundance of SOX9 protein [38]. SOX4 is expressed by human MSPC and downregulated during chondrogenic differentiation [39]. Notably, SOX4 and runt related transcription factor 2 (RUNX2), which are both implicated in regulation of chondrogenesis and osteogenesis, are targets of miR-30a, which is progressively downregulated with increasing chondrosarcoma grade, leading to a relative overexpression of SOX4 and RUNX2 [40]. Also, miR-129-5p, which targets SOX4, was significantly downregulated in human chondrosarcoma tissues, while SOX4 protein was activated [41]. Indeed, this imbalance of SOX9 and SOX4 may contribute to the incomplete chondrogenic differentiation and persistent proliferation of chondrosarcomas. In line with this, in chondrosarcoma cell lines miR-129-5p repressed WNT/β-catenin signaling by targeting SOX4 which repressed proliferation and invasion [41].

Also, adult AC contains MSPC expressing MSC related markers [42], which are predominantly localized in the superficial zone (SZ) [43,44] and undergo proliferation upon onset of OA [44]. Depending on the study, the human AC MSPC population was defined as positive for CD105 and CD166 [45–47], STRO-1 [48], NOTCH1 [49], CD166 and CD90 [50], STRO-1 and FGF2 [51] or CD106, STRO-1 and NOTCH1 [43,49]. The MSPC fraction makes up 3–17% of all AC resident cells and increases in human OA AC compared to normal adult AC [46,47,49,52]. Utilizing a colony-forming assay, Fellows et al. reported a doubling of the MSPC population in human OA AC compared to normal adult AC [53]. Moreover, it seems that especially OA AC contains two MSPC populations. One population consists of more committed cartilage progenitor cells exhibiting a limited proliferation potential and early senescence, which may either arise from dedifferentiated chondrocytes or activated cartilage inherent quiescent progenitors. A second population consists of rather multipotent stem cells, which are either inherent, since they are also found in normal adult AC, or which may be also recruited from adjacent tissues like bone marrow or synovium [53]. Whether the increase of MSPC number in OA AC is an attempt of cartilage intrinsic repair or rather a prerequisite for macroscopic cartilage degradation due to a lack of extracellular matrix (ECM) maintenance, respectively proliferation-associated degradation, remains elusive.

Culturing of human bone marrow-derived MSPC with rFGF2 reduced the cell size and turned the cell shape into a spindle-like fibroblastic-like appearance, which was accompanied by a faster growth, increased life span and an advance in chondrogenic potential [54–57]. FGF2 signaling was mediated by fibroblast growth factor receptor 1 (FGFR1) activity, which was rate limiting for self-renewal of human MSPC [58]. Interestingly, telomere length of MSPC expanded under rFGF2 increased. Since no telomerase activity was detected, FGF2 seems to selectively expand a subpopulation of cells with longer telomeres [59]. Moreover, in human MSPC FGF2 increased SOX5, SOX6 and SOX9 expression, which are all implicated in enhanced chondrogenesis [60], although siRNA-mediated knockdown of SOX9 did not prevent rFGF2-mediated chondrogenesis [57]. Notably, aging of human bone marrow derived MSPC progressively decreased FGF2 and FGFR1 expression, which coincided with reduced proliferative capacity of MSPC after prolonged cultivation [61].

Interestingly, around the age of 40, when chondrosarcoma incidence starts to rise, also MSPC in the SZ of AC start to proliferate and exhibit reorganization of cell arrangement which may be a prerequisite or early indicator of OA [62,63]. Collectively, this indicates a proliferation-inducing environment in cartilage and bone at that age in which increasing abundance of free FGF2 may be implicated.
**Figure 1.** Conflicting differentiation stimuli in chondrosarcoma. In chondrosarcoma cells signaling pathways simultaneously promoting or antagonizing chondrogenesis, stemness, osteogenesis and fibrogenesis are activated preventing differentiation in one or the other direction. Established positive stimuli are depicted as black arrows, established inhibitory stimuli are depicted as black bar-headed lines. Pathways, which are active in chondrosarcoma cells, but whose stimulatory function has not been clearly established in chondrosarcoma are shown as light gray arrows.

**Figure 2.** Chondrosarcoma signaling. Several growth factor and cytokine regulated signaling pathways are activated in central chondrosarcomas (black arrows). FGFR1, integrins, ADIPOR, CCR5 and CXCR4 are all capable of MAPK-ERK and PI3K-AKT signaling induction leading to MMP, RANKL and VEGF transactivation. Moreover ADIPOR, CCR5 and CXCR4 activate NF-κB and p38 MAPK signaling. In addition, signaling regulation is obtained by adaptor proteins like CCN2, which binds VEGF, FGF2 and FGFR1 or coreceptors including CD44. Chondrosarcoma cells actively excrete FGF2 and VEGF (gray arrow), which promotes angiogenesis by attracting endothelial cells.
3. Hypoxia and Angiogenesis in the Bone Niche

In the bone, chondrosarcoma cells interact with resident MSPC, HSC, mature immune cells, (pre)osteoblasts, (pre)osteoclasts and endothelial cells [21]. Chondrosarcoma growth dysregulates the balance between osteoblasts and osteoclasts leading to bone degradation, which might be mediated by increased RANKL expression by chondrosarcoma cells [64].

Without neovascularization the size of a tumor is inherently limited to 1–5 mm due to restricted oxygen and nutrient availability [65]. Although conventional chondrosarcomas remain poorly vascularized compared to other tumors [66,67], which may contribute to the cartilage like differentiation and systemic chemotherapy resistance, induction of angiogenesis is the major limiting step towards local invasion and metastasis. This is reflected by a low rate of vascularization in G1 conventional chondrosarcomas, which is largely enhanced in the significantly more aggressive G2 and G3 chondrosarcomas [66,68]. VEGF and FGF2, which have an intense crosstalk, are the two main growth factors involved in chondrosarcoma angiogenesis [65]. VEGF, FGF2, endothelin-1 (ET-1) and hypoxia-inducible factor-1α (HIF-1α) expression and mitogen activated protein kinase (MAPK) signaling are significantly enhanced in G2 and G3 conventional chondrosarcomas compared to G1 chondrosarcomas [65,68–72]. In addition, central chondrosarcomas commonly express FGFR1, whereas FGFR3 expression is rarely detected [13]. Moreover, high HIF-1α expression has been linked to shorter disease free and overall survival in chondrosarcoma patients [73,74].

Interestingly, dedifferentiated chondrosarcomas showed a high microvessel density without correlation to the grade of the tumor [67] or VEGF expression [70]. FGF2 exerts its pro-angiogenetic activities by interaction with a variety of surface receptors on endothelial cells including receptor tyrosine kinases, heparan-sulfate proteoglycans and integrins. Subsequently, endothelial cells upregulate VEGF, FGF2, OPN and cyclooxygenase 2 (COX-2) expression. Moreover, FGF2 induces the expression of inflammatory cytokines and acts as a direct chemoattractant for immune cells, which actively participate in neovascularization of various tumors [75]. C-X-C motif chemokine ligand 12 (CXCL12) is secreted in the bone marrow, where it mediates the homing of HSC [76]. C-X-C motif chemokine receptor 4 (CXCR4) is the receptor for CXCL12, which is typically expressed by HSC and mature immune cells. Both expression of CXCL12 and CXCR4 can be upregulated by HIF-1α under hypoxic conditions in several cell types [76]. Moreover, CXCR4 downstream signaling has been implicated in migration and metastasis of different tumors [76]. Notably, both CXCR4 and CXCL12 expression was increased in human chondrosarcoma tissues [77] and CXCR4 expression was also enhanced by hypoxia induced HIF-1α and VEGF-A expression in chondrosarcoma cell lines concomitantly with MMP1 expression [78–80], whereas CXCL12 induced VEGF-A secretion under hypoxic conditions [80], indicating a self-reinforcing system. In addition, miR-181a was overexpressed in high grade chondrosarcomas and its expression was upregulated by hypoxia in human chondrosarcoma cell lines. Regulator of G-protein signaling 16 (RGS16), a negative regulator of CXCR4 signaling is a direct target of miR-181a [78], implicating this miRNA in activation of CXCR4 signaling. C-C motif chemokine ligand (CCL5), also known as regulated upon activation, normally T-expressed, and presumably secreted (RANTES) has been implicated in downregulation of miR-199a in human chondrosarcoma cells, which promotes VEGF upregulation and angiogenesis [81].

In vitro, rFGF2 treated chondrosarcoma cells increased VEGF-C expression via downregulation of miR-381 [82]. In addition, CCN2, also known as connective tissue growth factor (CTGF), has been identified as a binding partner of VEGF-A (Figure 2). In complex with rCCN2, rVEGF-A was not able to induce angiogenesis in a human in vitro system as well as in vivo in mice [83]. The CCN2-VEGF-A complex could be dissociated by CCN2 cleavage by MMP-1, MMP-3, MMP-7 and MMP-13 reactivating the angiogenetic activity of VEGF-A in vitro and in a matrigel injection model in mice [84]. Indeed, in high grade chondrosarcomas CCN2 mRNA was downregulated compared to low grade chondrosarcomas [85]. In contrast, rCCN6 promoted angiogenesis in human chondrosarcoma cell lines SW1353 and JJ012 by induction of VEGF-A expression through inhibition of miR-452, which interacts with the 3′UTR of the human VEGF-A gene repressing its transcription [86].
Notably, Wang et al. showed that human growth plate cartilage expressed the NH2-propeptide of the cartilage-characteristic collagen type IIB splice variant (PIIBNP), which was capable of killing both human chondrosarcoma and carcinoma cells upon binding of αvβ3 and αvβ5 integrins in vitro [87]. These integrin types were not expressed on cells of human developing cartilage, whereas adult human AC cells expressed low levels [88]. In contrast, human osteoclasts and endothelial cells express high levels of αvβ3 and αvβ5 integrins [89,90], indicating that they are actively excluded from the growth plate. Whether PIIBNP is also present in adult healthy or OA AC has not been investigated.

In summary, vascularization is an important step during chondrosarcoma progression and appears to be predominantly mediated by VEGF and FGF2. Whereas avascularity of developing cartilage seems to be ensured by active exclusion of endothelial cells.

4. Local Invasion and Metastasis

Catabolic degradation of the ECM, an important prerequisite for migration and tumor cell invasion, is predominantly mediated by MMP [91]. Basically, MMP expression is a stem cell feature [92], but also differentiated cells may upregulate MMP expression upon senescence [93] or inflammation [94]. MMP-1, MMP-2, MMP-3, MMP-7, MMP-9 and MMP-13 are frequently expressed in chondrosarcoma tissues [95,96]. In addition, high levels of MMP-26 were detected in chondrosarcoma samples by Xu et al. [97]. Increased MMP-1 expression has been linked to poor outcome in chondrosarcoma patients [95] and also promotes invasiveness of human chondrosarcoma cells in vitro [98]. A single nucleotide polymorphism (SNP) frequently found in the promoter region of MMP-1 in human chondrosarcoma tissues and established chondrosarcoma cell lines [99] generates an artificial avian erythroblastosis virus E26 oncogene homolog (ETS) binding site, which has been implicated in enhanced MMP-1 expression in several carcinomas [100]. Especially in high grade central chondrosarcomas increased MMP-2 levels have been documented [101,102]. But also expression of MMP-3, MMP-7 and MMP-13 increased with tumor grade [103]. Often, MMP expression was highly variable in different areas of a single chondrosarcoma [104]. Moreover, MMP-1, MMP-7 and MMP-9 expression was found to be highest in the invasive protrusions of chondrosarcomas [95,103].

Also, elevated expression of pro-inflammatory CCL5, CCL3 and their receptor C-C motif chemokine receptor 5 (CCR5), which is a typical surface protein of macrophages and T-cells, has been detected in human chondrosarcoma tissues (Figure 2) [105]. In vitro, rCCL3 induced MMP-2 expression and migration in the J012 chondrosarcoma cell line, which was mediated by AMPK-activated protein kinase (AMPK), p38 MAPK and nuclear factor kappa B (NF-κB) [102]. rCCL5 induced MMP-3 expression and migration via phosphatidylinositol 3-kinase (PI3K), v-Akt murine thymoma viral oncogene homolog (AKT) and NF-κB in the same chondrosarcoma cell line [105].

Adipose tissue may function as endocrine organ by secretion of adipokines including pro-inflammatory cytokines [106]. Resistin, also known as adipose tissue-specific secretory factor (ADSF), has been identified as peptide hormone secreted by murine adipose tissue. Notably, in humans especially, monocytes express resistin [107]. High resistin levels in human chondrosarcoma tissues have been linked to MMP-2 expression and r-resistin promoted invasiveness and MMP-2 expression in human chondrosarcoma cells in vitro mediated by AMPK and p38 MAPK [108]. Another adipokine implicated in chondrosarcoma migration and angiogenesis is adiponectin, which is increasingly upregulated with the histological grade of conventional chondrosarcoma [109]. In addition, elevated expression of the two adiponectin receptors ADIPOR1 and ADIPOR2 mRNA was detected in human chondrosarcoma tissues and cell lines [110]. In chondrosarcoma cell lines, r-adiponectin promoted VEGF-A expression via ADIPOR activating the PI3K-AKT-mTOR pathway and HIF-1α [109]. Migration was induced via ADIPOR activating AMPK, p38 and NF-κB pathways [110].

ET-1 is a peptide hormone secreted by vascular endothelial cells and monocytes [111]. COX-2, a key enzyme in prostaglandin biosynthesis, mediates inflammation, angiogenesis and cancer progression [112]. Significant ET-1 and COX-2 expression in human chondrosarcoma tissues has...
been linked to chondrosarcoma cell migration in vitro. In JJ012 cells rET-1 increased COX-2 expression via ET-receptors, MAPK, and activator protein 1 (AP-1) signaling.

OPN is secreted by bone cells like osteoblasts and osteoclasts, but also immune cells and endothelial cells [113]. It demonstrably promotes progression of different cancers by enhancing proliferation, survival, angiogenesis, motility, and invasion. In the bone, its main functions are the regulation of mineralization and remodeling [113]. The expression of OPN can be upregulated by different growth factors including FGF2 in murine endothelial cells [114,115], whereas OPN is involved in COX-2 and HIF-1α dependent VEGF expression in human carcinoma and melanoma [114]. rOPN increased MMP-9 expression and migration of JJ012 chondrosarcoma cells through αvβ3 integrin, focal adhesion kinase (FAK), MAPK/ERK kinase (MEK), extracellular signal-regulated kinase (ERK) and NF-κB signaling [116].

In human HCS-2/8 chondrosarcoma cells rFGF2 induced MMP-13 expression [72]; rCCN2, which interacts both with FGF2 and FGFR, increased MMP-13 expression and migration in human JJ012 cells in vitro via αvβ3 integrin, FAK, ERK, and NF-κB [117]. In addition, rMMP-3 has been shown to upregulate the expression of CCN2 in the human chondrosarcoma cell line HCS-2/8 in vitro [118]. However, in human high-grade chondrosarcoma tissues CCN2 mRNA was reduced compared to low grade chondrosarcomas [85]. rCCN6 enhanced migration of the human chondrosarcoma cell line JJ012 by increasing intercellular adhesion molecule 1 (ICAM-1) expression via αvβ3 and αvβ3 integrins, FAK and MAPK signaling [119].

Collectively, these data indicate that the signaling events that induce MMP-based ECM degradation and local invasion are closely interconnected to those that mediate inflammation and angiogenesis. Yet, metastasis can only occur when cancer cells are able to settle down and proliferate in a foreign environment [120]. For chondrosarcoma, the lung is the primary site of metastasis [5], albeit further research is needed to elucidate the reasons for this and how it may be prevented.

5. Primary Cilia in Chondrogenesis, Cartilage Maintenance and Chondrosarcoma

In mammals, primary cilia mediate cellular responses to mechanical load but also substrate texture by activation of different signaling pathways including wingless-type MMTV integration site family (WNT) and hedgehog (Hh) [121–123]. Loss of primary cilia in human MSPC inhibited adipogenic and osteogenic differentiation to a greater extent than chondrogenic differentiation (Figure 1) [124]. Nevertheless, chondrogenesis of human MSPC can be induced by dynamic compression of 3D cultures [125–127], which has to be perceived by the cells through an appropriate mechanism which may be localized in the primary cilia. Interestingly, MSPC in the SZ of human OA AC seem to have more and longer cilia compared to cells in healthy AC [128]. This difference in cilia length has been also demonstrated in the SZ of bovine AC [129]. In human MSPC increased cilia length has been associated with decreased WNT signaling and decelerated proliferation [123]. Indeed, primary cilia claim the basal body and therefore the centrosome for assembly, which means that primary cilia have to be disassembled for the formation of the mitotic spindle, which takes more time the longer the cilium is [130]. On the other hand, fast growing cells may not have the time to assemble primary cilia between cell divisions. In tumor cells, both the lack of primary cilia but also formation of multiple cilia due to inhibited cytokinesis in multinucleated cells with several centrosomes has been described [131]. Human chondrosarcoma cells lose primary cilia with increasing malignity [132], which may be either a consequence of rapid proliferation or the prerequisite for enhanced cell cycle progression. Recently, histone deacetylase 6 (HDAC6) has been implicated in suppression of cilia formation in human chondrosarcoma [133]. Notably, osteochondroma have a random cilia orientation compared to normal growth plate chondrocytes where cilia are arranged parallel to the growth axis, which assures the correct assembly of chondrocytes in stacked columns [134]. Upon closure of the growth plate usually also osteochondroma growth stops [135]. However, resting MSPC in the metaphysis of long bones may be reactivated during formation of secondary chondrosarcoma [14]. In summary, the progressive
loss of primary cilia in conventional chondrosarcomas may foster chondrogenic differentiation, but also facilitate proliferation.

6. Chondrosarcoma Treatment

6.1. State of the Art

The risk of local recurrence and metastasis of conventional chondrosarcomas largely increases with histological grade [6]. For low grade tumors intralesional excision may be sufficient [136], whereas surgery with wide margins has become the primary care for malignant cartilage lesions [137]. Yet, depending on the location in the skeleton, wide resection may not be possible [138,139] and adjuvant therapies may be needed. Unfortunately, conventional chondrosarcomas are highly resistant both to radiation and chemotherapy [139–141]. Chemoresistance of chondrosarcoma may be due to slow proliferation, multidrug resistance protein 1 (MDR1) overexpression [142,143], poor vascularity [66,67] and dense hyaline ECM [144] when compared to other cancers. Notably, under moderate hypoxic conditions (5% O₂) radiation resistance of chondrosarcoma cell lines was significantly higher compared to standard cell culture conditions (21% O₂) [141], indicating that prevalent hypoxia may also interfere with radiation response in chondrosarcoma. Yet, there are publications indicating sustained stable disease after chemotherapy in palliative care for some patients with dedifferentiated chondrosarcoma [8,145–147]. Also, proton beam radiation therapy resulted in sustained local control of some chondrosarcomas of the skull base [148]. Besides, carbon ion radiation may be useful for inoperable pelvic chondrosarcomas [149].

In addition, chondrosarcomas tend to be genetically instable with loss of heterozygosity at many loci [150,151], which exacerbates identification of relevant targets and raises the question whether single agent approaches may be applicable at all. Moreover, many older studies investigating genetic aberrations and potential target proteins in chondrosarcoma did not distinguish between different subtypes and gradings.

In summary, there is an urgent need for new targeted therapies in chondrosarcoma which are discussed in the following paragraphs.

6.2. Targetting the Hh Pathway

The Hh pathway is involved in stem cell proliferation and differentiation during development and tissue regeneration [152]. In addition, Hh signaling is also implicated in the formation and progression of several kinds of cancer, including basal cell carcinoma, medulloblastoma, osteosarcoma, Ewing sarcoma and rhabdomyosarcoma [153–157]. The Hh pathway is activated by binding of one of the three human ligands (IHH, DHH, SHH) to the patched 1 (PTCH1) receptor. Subsequently, smoothened (SMO) initiates downstream signaling via the glioma associated oncogene family (GLI) transcription factors [158]. Depending on the tumor, aberrant Hh pathway activation may be mediated by ligand overexpression or PTCH loss-of-function mutations. But also ligand-independent activation via SMO gain-of-function mutations, respectively constitutive overexpression and activation of GLIs is possible [154]. Yan et al., 2008 detected a single SMO mutation in a selection of dedifferentiated chondrosarcomas. All SNPs detected in the PTCH1 gene of chondrosarcomas resulted in silent alterations [159]. Therefore, mutations in the Hh pathway seem to be infrequent in chondrosarcomas. However, Tiet et al., 2006 reported a constitutive active Hh pathway in human chondrosarcoma explant cultures similar to growth plate chondrocytes, although in high grade chondrosarcomas IHH, PTCH1 and GLI1 mRNA expression declined when compared to low grade lesions [160,161]. Also in peripheral chondrosarcomas PTCH1, GLI1 and GLI2 mRNA expression was reduced compared to benign osteochondromas [162].

Indeed, in animal models ligand dependent Hh signaling required primary cilia [122]. Therefore, drug efficacy of SMO inhibitors like vismodegib (GDC-0449) or saridegib (IPI-926) is probably dependent on the presence of primary cilia, where Hh pathway components have been shown
to be concentrated in murine chondrocytes [163]. Yet, Ho et al. observed that most chondrosarcoma and enchondroma cells (70–100%) lack primary cilia, whereas 65% of human AC chondrocytes had primary cilia [132]. Notably, ablation of primary cilia in chondrosarcoma explants enhanced Hh pathway regulated transcription, probably via prevention of GLI3 processing in its repressor form, whereas the SMO inhibitor cyclopamine was ineffective in these cells [132].

With this in mind, it is not surprising that GDC-0449 did not meet the primary endpoint in a phase II clinical trial with chondrosarcoma patients, although some patients with grade I or II chondrosarcomas seemed to benefit from the treatment [164]. Also the results of a phase II trial using IPI-926 for treatment of chondrosarcoma patients were discouraging [5].

Potentially, the use of Hh pathway inhibitors acting downstream of SMO like HPI-4 may be more successful in chondrosarcoma treatment by means of targeting cancer stem cells and early grade chondrosarcoma cells [165], but maybe also later stages as its mechanism of action is not necessarily dependent on the presence of primary cilia. In the SW1353 chondrosarcoma cell line the use of arsenic trioxide (ATO) induced G2/M cell cycle arrest and apoptosis as well as autophagy. In addition to the GLI transcription factors ATO has several other targets and indeed, autophagy induction in SW1353 cells was reported to depend on mTOR inhibition [166]. Thus, using ATO alone or in combination with other substances may aid to develop novel treatment strategies for chondrosarcomas.

6.3. Targetting IDH1, IDH2 and HDACs

The isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) in the Krebs cycle and concomitantly produce nicotinamide adenine dinucleotide phosphate (NADPH) from NADP+ [167]. Missense mutations at arginine 132 in IDH1 or the homologous arginine 172 in IDH2 occur in 80–90% of enchondromas [168,169] and 50–60% of central chondrosarcomas with IDH1 mutations dominating [170]. Also, dedifferentiated chondrosarcomas predominantly contain IDH1 mutations [171]. Indeed, IDH mutations seem to be an early event in chondrosarcoma genesis [171]. The mutant enzymes have a modified enzymatic activity reducing α-KG under consumption of NADPH to the onco-metabolite R(−)-2-hydroxyglutarate (2-HG) [167].

IDH mutations are always restricted to one allele and it seems that the presence of the wild type protein in a homodimer increases the capacity of 2-HG generation [172]. Many cellular enzymes are dependent on the presence of α-KG including the Ten-Eleven-Translocation (TET) protein family reducing DNA methylation, the JumonjiC domain-containing (JmjC) histone demethylases altering histone methylation, prolyl and lysyl hydroxylases implicated in collagen folding and maturation, and prolyl hydroxylases (PHD) regulating hypoxia-inducible factor (HIF) protein degradation [172].

Thus, mutant IDH is capable of altering the epigenetic state of cells leading to DNA and histone hypermethylation which affects differentiation [173] and impairs collagen maturation as well as oxygen homeostasis [174]. Indeed, generation of 2-HG not only reduces α-KG abundance but 2-HG directly inhibits enzymes dependent on α-KG by occupying the binding site [172].

In human MSPC, the expression of the IDH1 R132C mutant also upregulated global histone methylation, but repressed osteogenic differentiation and induced chondrogenic differentiation (Figure 1) indicated by SOX9 and collagen type II α1 chain (COL2A1) expression, whereas no functional cartilage matrix was deposited [175]. This effect might contribute to the incomplete chondrogenic differentiation of chondrosarcomas.

Inhibition of the mutant IDH1 in the human chondrosarcoma cell line JJ012 (IDH1 R132G) by AGI-5198 significantly reduced 2-HG production, colony formation and migration and induced apoptosis [176], illustrating that IDH1 inhibition may have therapeutic value.

Indeed, different clinical studies targeting IDH mutant chondrosarcomas and other tumors are currently ongoing. The NCT0273739 phase I/II, multicenter study has been actually completed. In this study, AG-221, an oral IDH2 inhibitor, has been tested in patients with advanced solid tumors, including gliomas, angioimmunoblastic T-cell lymphomas and chondrosarcomas with an IDH2 mutation. In two other ongoing phase I studies (NCT02481154/NCT02073994), the IDH inhibitors
AG-881 and AG-120 are under clinical evaluation for advanced solid tumors that harbor an IDH1 and/or IDH2 mutation, including gliomas, cholangiocarcinomas and chondrosarcomas. In addition, there is a phase Ib, open-label, single-center, nonrandomized study recruiting patients that evaluates the toxicity and efficacy of the antidiabetic drug metformin in combination with the antimalarial drug chloroquine in IDH1/2 mutated patients with a glioma, intrahepatic cholangiocarcinoma or chondrosarcoma (NCT02496741) [177].

In addition to methylation, acetylation of histones regulates gene expression and differentiation. Since many tumors exhibit aberrant histone modifications, HDAC inhibitors have emerged as new class of anticancer drugs [178]. Indeed, the HDAC inhibitor depsipeptide (romidepsin) induced growth arrest, apoptosis and differentiation in human chondrosarcoma cell lines in vitro [179]. A phase II study (NCT00112463) including extra-skeletal chondrosarcoma patients treated with romidepsin has been actually completed. Whether IDH inhibition or HDAC inhibition is indeed a beneficial therapy in chondrosarcoma remains to be demonstrated.

In line with chondrosarcomas, accumulating evidence also shows epigenetic dysregulation in OA [180,181]. However, IDH mutations have not been detected in AC so far, but inflammatory cytokines suppressed IDH and TET activity in human primary chondrocytes in vitro [182], a mechanism which might also apply in chondrosarcomas without IDH mutation.

6.4. Targeting the PI3K-AKT-mTOR and SRC Pathway

AKT kinases are highly active in human chondrosarcomas [183,184]. Indeed, PI3K-AKT signaling is activated by many growth factors including FGF2 and IGF1 as well as inflammatory cytokines like CCL5 (Figure 2), which have been implicated in chondrosarcoma genesis and progression [185]. In addition, p70 S6 kinase (p70S6K) activation was increased with histological grade of conventional chondrosarcomas and has been also detected in dedifferentiated chondrosarcomas [186]. P70S6K is a downstream target of mTOR in the PI3K-AKT pathway phosphorylating the ribosomal S6 protein, which enhances protein synthesis [5]. However, activating mutations in the PI3K-AKT pathway are very rare in chondrosarcomas [187]. Although IGF1R positivity of human central chondrosarcomas increases with histological grade, IGF1R inhibition did not impair proliferation or migration of chondrosarcoma cell lines in vitro [188]. Treatment with BEZ235, a PI3K/mTOR inhibitor, significantly reduced growth of chondrosarcoma cell lines in vitro and in a murine xenograft model [186]. In a rat chondrosarcoma model, the use of the mTOR inhibitor everolimus suppressed tumor progression and delayed recurrence of microscopic residual disease [189]. Moreover, in a small retrospective study with patients with unresectable chondrosarcoma a combination of sirolimus (rapamycin) inhibiting mTOR and the chemotherapeutic agent cyclophosphamide was successful in disease control in 70% of patients during a period of several months [190]. Yet, a phase II clinical trial (NCT02008019) utilizing everolimus in patients with primary or relapsed chondrosarcomas has been suspended in 2016 due to unavailability of everolimus.

Aberrant activation of SRC kinase signaling has been detected in human chondrosarcoma tissues [183,191]. SRC is a common mediator of growth factor and integrin signaling and may also act upstream of PI3K-AKT [185]. Together SRC and AKT activate survival pathways and HIF1α, which is upregulated in high grade chondrosarcoma tissues [73,74].

Dasatinib (BMS354825), which targets SRC as well as Abelson tyrosine protein kinase (ABL), KIT and platelet derived growth factor receptor (PDGFR) decreased viability of chondrosarcoma cell lines in vitro [183,192]. Moreover, dasatinib especially sensitized p53 mutant chondrosarcoma cell lines to doxorubicin treatment, indicating a potential of dasatinib to overcome chemoresistance [191]. Nevertheless, in the SRC009 phase II trial, the use of dasatinib as single agent in pretreated, high-grade sarcomas, including chondrosarcomas showed no benefit [193]. Therefore, inhibition of PI3K-AKT-mTOR and SRC might be advantageous in combination therapy of chondrosarcoma patients, although reliable clinical data are still missing.
6.5. Targeting Angiogenesis and Invasion

As already discussed in chapter 3 and 4, both VEGF and FGF2 signaling are activated in chondrosarcomas and apparently contribute to angiogenesis and invasion. Since enhanced activation of PDGFR has been shown in human chondrosarcoma cell lines in vitro [183], PDGFR may be a therapeutic target as well. SU6668, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), PDGFR-β and FGFRI induced growth inhibition in chondrosarcoma animal models, which seems to be attributed to the antiangiogenic effects of SU6668 [194]. The ongoing NCT01330966 phase II study is investigating the efficacy and safety of the single agent pazopanib, inhibiting KIT, PDGFR and VEGFR among other enzymes [195], in patients with unresectable or metastatic chondrosarcoma. Another phase II trial (NCT02389244) currently recruiting patients utilizes regorafenib, an oral multikinase inhibitor, which targets VEGFR, tyrosine kinase with Ig and EGF homology domains-2 (TIE2), KIT, rearranged during transfection (RET), RAF-1, BRAF, BRAFV600E, PDGFR and FGF, in patients with metastatic bone sarcomas including chondrosarcomas. Sorafenib, a multi-kinase inhibitor inhibiting several tyrosine kinases including VEGFR, PDGFR and RAF, mediated pMEK and pERK inhibition leading to growth arrest and apoptosis in the chondrosarcoma cell lines SW1353 and CRL7891, which was accompanied by downregulation of cyclin D1, retinoblastoma susceptibility protein (RB), B-cell lymphoma-extra large (BCL-XL) and myeloid cell leukemia sequence 1 (MCL-1) expression [196]. Two phase II studies utilizing sorafenib in patients with different types of sarcomas indicated prolonged stable disease when evaluated in 3 chondrosarcoma patients [197,198]. Moreover, imatinib, another multi-kinase inhibitor, inhibiting ABL, KIT and PDGFR, was tested in a phase II trial with patients having recurrent, non-resectable, PDGFR positive chondrosarcomas. However, in this trial no benefit of imatinib treatment has been reported [199]. Another open-label study (NCT00928525) utilizing imatinib in chondrosarcoma patients is ongoing. Once data of the ongoing trials are available, it may be determined, whether the use of multikinase inhibitors is a therapeutic option for chondrosarcoma patients.

6.6. Additional Targets and Biomarker

In addition to the pathways mentioned in the previous chapters that are currently being investigated in clinical trials, there may be other signaling pathways involved in chondrosarcoma genesis and progression that could serve as potential novel targets.

Canonical WNT signaling is implicated in the β-catenin-dependent regulation of mitotic and cell fate-determining gene transcription of MSPC, whereas two non-canonical WNT pathways affect cell shape and motility in the planar cell polarity pathway and the Ca^{2+}/WNT pathway [200]. Dickkopf WNT signaling pathway inhibitor 1 (DDK1), an antagonist of canonical WNT/β-catenin signaling as well as β-catenin were progressively overexpressed in chondrosarcoma tissues with increasing histological grade and correlated with poor prognosis [201]. In the chondrosarcoma cell line SW1353 WNT3A, WNT6, WNT7B and frizzled-3 (FZD3) mRNA expression was upregulated compared to MSPC and rWNT3A enhanced SW1353 proliferation [202]. Recombinant WNT inhibitory factor 1 (WIF1), which inhibits WNT signaling by binding of several WNT ligands including WNT3A and WNT5A, prevented WNT induced MSPC growth by neutralizing rWNT3A-mediated inhibition of chondrogenesis in micromass cultures of embryonic chick limb bud cells [203]. WIF1 is epigenetically silenced via promoter methylation in human chondrosarcoma tissues and cell lines, and loss of WIF1 protein expression correlated with lower progression free and overall survival rates [204]. Interestingly, aging reduced expression of β-catenin in bone marrow derived MSPC, while β-catenin phosphorylation increased, indicating enhanced proteasomal degradation [61]. Therefore, targeting of WNT signaling might be of interest for chondrosarcoma treatment.

NOTCH signaling maintains the stem cell phenotype and prevents differentiation of different types of MSPC. In 3D cultures of hMSPC NOTCH signaling was downregulated with increased chondrogenic differentiation. Indeed, jagged 1 (JAG1) overexpression prevented chondrogenesis in hMSPC [60]. In adult AC NOTCH1 expression is restricted to MSPC in the SZ which proliferate during
the onset of OA and form clusters [49]. In a human conventional chondrosarcoma of the maxilla strong NOTCH3 and JAG1 protein expression was detected at areas of tumor proliferation [205]. Increased NOTCH1, hairy and enhancer of split 1 (HES1), hairy/enhancer-of-split related with YRPW motif (HEY) 1 and HEY2 protein expression indicating active NOTCH signaling has been detected in human chondrosarcoma tissues [206]. In conclusion, inhibition of NOTCH signaling might impede proliferation and induce differentiation in chondrosarcomas.

Intriguingly, 96% of high grade central chondrosarcomas harbor alterations in the p53 or RB tumor suppressor pathways [207]. Inactivating p53 mutations especially occur in G3 chondrosarcomas [2], indicating a rather late event. In addition, amplification of 12q13 and loss of 9p21 are common genetic changes in advanced chondrosarcomas [135]. Indeed, the genes for mouse double minute 2 (MDM2), negatively regulating p53, and cyclin dependent kinase 4 (CDK4), important for G1 cell cycle progression, are localized at 12q13, whereas 9p21 contains the cyclin dependent kinase inhibitor 2A (CDKN2A) locus, coding for the tumor suppressor proteins p16INK4A and alternative reading frame (ARF) [208,209]. Lack of p16INK4A was implicated in the radiation resistance of human chondrosarcoma cell lines in vitro [141]. Although the loss of these tumor suppressor genes is frequently found in advanced chondrosarcomas, their inactivation might be also a result of increasing genomic instability [150,151] and not the primary cause of tumor progression.

Programmed cell death ligand 1 (PD-L1) expression, either by tumor cells themselves or by the tumor-associated immune cells, can be an effective mechanism for tumors to evade T-cell recognition and destruction [210]. Indeed, 41% of dedifferentiated chondrosarcomas examined in a study of Kostine et al. displayed PD-L1 positivity. Preliminary results of the SARC028 phase II study utilizing the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced soft tissue and bone sarcomas showed in one out of six dedifferentiated chondrosarcoma patients a partial tumor remission [5] indicating a potential use of this therapy in a subset of chondrosarcoma patients.

As already discussed in the previous chapters, several miRNAs are dysregulated in their expression in human chondrosarcomas [211]. However, functional implication in chondrosarcoma tumorigensis has yet only been attributed to a few of them, although many have distinct functions in other types of cancer. Depletion of two miRNAs has been implicated in chemoresistance; miR-100 is downregulated in human chondrosarcoma tissues and cell lines. In vitro, depletion of miR-100 resulted in cisplatin resistance of chondrosarcoma cells probably mediated by mTOR, which is a direct target of miR-100 [212]. Low miR-125b level have been associated with doxorubicin resistance of chondrosarcoma cells in vitro [213]. In the human chondrosarcoma cell line JJ012 predominantly NOTCH and IGF signaling were deregulated by reduced endogenous miRNA levels [214]. Hence, the interest in miRNAs in cancer is consistently growing.

Although some individual targets seem to be promising for chondrosarcoma treatment, in the clinic, the use of single targeted drugs just like chemotherapeutics and radiation is often disappointing. This might be due to global epigenetic and genomic changes in chondrosarcoma, but also some special features including poor vascularity and dense ECM accompanied by permanent activation of stem cell pathways preventing differentiation. In addition, the rarity of chondrosarcomas prevents initiation of large stratified trials.

7. Conclusions

Chondrosarcomas are a heterogenic group of rare tumors. Basically, some entities seem to arise from MSPC of the growth plate in adolescents and young adults. On the other hand, quite unusual for bone sarcomas, the peak incidence of conventional and dedifferentiated chondrosarcomas in adults beyond the age of 40. Indeed, these chondrosarcomas seem to originate from MSPC in the bone marrow, but not necessarily in the long bones. High grade conventional, but especially dedifferentiated chondrosarcomas have an irregular appearance, with zones of rather chondrogenic and areas of rather fibrogenic or osteogenic differentiation, that together indicate conflicting signaling, or even a heterogenous pool of MSPC, which prevents differentiation in one or the other direction.
Cartilaginous differentiation is a challenge for tumor growth, as avascularity—a hallmark of cartilage—limits the growth rate. Actually, low grade conventional chondrosarcomas do slowly grow and are rather benign. However, once vascularization is induced, conventional and dedifferentiated chondrosarcomas tend to be locally aggressive and also frequently metastasize to the lung. In addition, high grade conventional chondrosarcomas and dedifferentiated chondrosarcomas exhibit a remarkable therapeutic resistance comprising chemotherapy, radiation therapy, but also targeted approaches. This has been attributed to comparatively slow proliferation, MDR1 overexpression, relatively poor vascularization and a dense hyaline ECM. Sustained stemness as well as global epigenetic and genomic changes seem to be implicated in therapeutic resistance of chondrosarcomas. In addition to the challenge to identify relevant targets for this rare disease, single agent approaches may be not applicable at all. Due to various subtypes and grading specific differences, identification of biomarkers for stratification of chondrosarcoma patients is urgently needed. Actually, clinical trials targeting mutant IDH, HDAC, PI3K/AKT/mTOR and SRC signaling as well as FGF2, VEGF and PDGF pathways are ongoing and have to be evaluated. Furthermore, immunotherapy has to be considered as a therapeutic option.

Notably, at the age beyond 40 at which the conventional and dedifferentiated chondrosarcoma incidence starts to rise, also MSPC in the SZ of AC start to proliferate and exhibit reorganization of cell arrangement which may be a prerequisite or early indicator of OA. Collectively, this indicates a changed microenvironment in cartilage and bone, in which an increasing abundance of free FGF2 might be implicated, since FGF2 signaling is involved in proliferation, migration, inflammation and angiogenesis. To date, it has not been investigated whether chondrosarcoma patients may additionally suffer from progressive OA or obesity. Such data may help to answer whether both diseases induce a growth factor and cytokine milieu that is supportive of chondrosarcoma growth and progression once chondrosarcoma-specific genetic and epigenetic aberrations have occurred in bone marrow MSPC.

Acknowledgments: The article processing charge was funded by the German Research Foundation (DFG) and the University of Freiburg in the funding program Open Access Publishing.

Author Contributions: Karen A. Boehme wrote the initial manuscript and all authors discussed and edited it until it reached its current form.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

- 2-HG: R(−)-2-hydroxyglutarate
- α-KG: α-ketoglutarate
- ABL: Abelson tyrosine protein kinase
- AC: articular cartilage
- ADIPOR: adiponectin receptor
- ADSF: adipose tissue-specific secretory factor
- AKT: v-Akt murine thymoma viral oncogene homolog
- AMPK: AMP-activated protein kinase
- AP-1: activator protein 1
- ARF: alternative reading frame
- ATO: arsenic trioxide
- BCL-XL: B-cell lymphoma-extra large
- CCL: C-C motif chemokine ligand
- CCR: C-C motif chemokine receptor
- CD: cluster of differentiation
- CDK4: cyclin dependent kinase 4
- CDKN2A: cyclin dependent kinase inhibitor 2A
- COL2A1: collagen type II α 1 chain
- COX-2: cyclooxygenase 2
- CTGF: connective tissue growth factor
| Acronym | Description |
|---------|-------------|
| CXCL12 | C-X-C motif chemokine ligand 12 |
| CXCR4 | C-X-C motif chemokine receptor 4 |
| DHH | desert hedgehog |
| DDK1 | dickkopf WNT signaling pathway inhibitor 1 |
| ECM | extracellular matrix |
| ERK | extracellular signal-regulated kinase |
| ET-1 | endothelin-1 |
| ETS | avian erythroblastosis virus E26 oncogene homolog |
| FAK | focal adhesion kinase |
| FGF2 | fibroblast growth factor |
| FGFR1 | fibroblast growth factor receptor 1 |
| FZD3 | frizzled-3 |
| GLI | glioma associated oncogene family |
| HDAC6 | histone deacetylase 6 |
| HES1 | hairy and enhancer of split 1 |
| HEY | hairy/enhancer-of-split related with YRPW motif |
| Hh | hedgehog |
| HIF-1α | hypoxia-inducible factor-1α |
| HLA-DR | human leukocyte antigen—antigen D related |
| HSC | hematopoietic stem cells |
| ICAM | intercellular adhesion molecule |
| IDH | isocitrate dehydrogenase |
| IGF | insulin like growth factor |
| IGF1R | insulin like growth factor 1 receptor |
| IHH | indian hedgehog |
| ISCT | International Society for Cellular Therapy |
| JAG1 | jagged 1 |
| JMJC | jumonjiC domain-containing |
| MAPK | mitogen activated protein kinase |
| MCL-1 | myeloid cell leukemia sequence 1 |
| MDM2 | mouse double minute 2 |
| MDR1 | multidrug resistance protein 1 |
| MEK | MAPK/ERK kinase |
| MMP | matrix metalloproteinases |
| MSC | mesenchymal stem cells |
| MSPC | mesenchymal stem and progenitor cells |
| mTOR | mammalian target of rapamycin |
| NADPH | nicotinamide adenine dinucleotide phosphate |
| NF-κB | nuclear factor kappa B |
| NOTCH | notch homolog |
| OA | osteoarthritis |
| OPN | osteopontin |
| p70S6K | p70 S6 kinase |
| PDGFR | platelet derived growth factor receptor |
| PHD | prolyl hydroxylase |
| PI3K | phosphatidylinositol 3-kinase |
| PIIBNP | collagen type IIB splice variant |
| PD-L1 | programmed cell death ligand 1 |
| PGP-1 | phagocytic glycoprotein 1 |
| PTCH1 | patched 1 |
| r | recombinant |
| RANKL | receptor activator of NF-κB ligand |
| RANTES | regulated upon activation, normally T-expressed, and presumably secreted |
RB retinoblastoma susceptibility protein
RET rearranged during transfection
RGS16 regulator of G-protein signaling 16
RUNX2 runt related transcription factor 2
SHH sonic hedgehog
SMO smoothened
SNP single nucleotide polymorphism
SOX SRY-related HMG box-containing
STRO-1 stromal cell surface marker-1
SZ superficial zone
TIE2 tyrosine kinase with Ig and EGF homology domains-2
TET ten-eleven-translocation
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
WHO World Health Organization
WIF1 WNT inhibitory factor 1
WNT wingless-type MMTV integration site family

References
1. Fletcher, C.D.M.; Bridge, J.A.; Hogendoorn, P.C.W.; Mertens, F. Who Classification of Tumours of Soft Tissue and Bone, 4th ed.; WHO 2013; IARC WHO Classification of Tumours: Lyon, France, 2013; Volume 5.
2. Hogendoorn, P.C.; Group, E.E.W.; Athanasou, N.; Bielack, S.; De Alava, E.; Dei Tos, A.P.; Ferrari, S.; Gelderblom, H.; Grimer, R.; Hall, K.S.; et al. Bone sarcomas: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21 (Suppl. 5), v204–v213. [CrossRef] [PubMed]
3. Allen, K.D.; Golightly, Y.M. State of the evidence. Curr. Opin. Rheumatol. 2015, 27, 276–283. [CrossRef]
4. Neogi, T.; Zhang, Y. Epidemiology of osteoarthritis. Rheum. Dis. Clin. N. Am. 2013, 39, 1–19. [CrossRef]
5. Polychronidou, G.; Karavasilis, V.; Pollack, S.M.; Huang, P.H.; Lee, A.; Jones, R.L. Novel therapeutic approaches in chondrosarcoma. Future Oncol. 2017, 13, 637–648. [CrossRef] [PubMed]
6. Fiorenza, F.; Abudu, A.; Grimer, R.J.; Carter, S.R.; Tillman, R.M.; Ayoub, K.; Mangham, D.C.; Davies, A.M. Risk factors for survival and local control in chondrosarcoma of bone. J. Bone Jt. Surg. Br. 2002, 84, 93–99. [CrossRef] [PubMed]
7. Qasem, S.A.; DeYoung, B.R. Cartilage-forming tumors. Semin. Diagn. Pathol. 2014, 31, 10–20. [CrossRef]
8. Grimer, R.J.; Goshgeher, G.; Taminiau, A.; Biau, D.; Matejovsky, Z.; Kollerler, Y.; San-Julian, M.; Gherlinzoni, F.; Ferrari, C. Dedifferentiated chondrosarcoma: Prognostic factors and outcome from a european group. Eur. J. Cancer 2007, 43, 2060–2065. [CrossRef] [PubMed]
9. Aigner, T.; Dertinger, S.; Neureiter, D.; Kirchner, T. De-differentiated chondrosarcoma is not a ‘de-differentiated’ chondrosarcoma. Histopathology 1998, 33, 11–19. [CrossRef] [PubMed]
10. Dornauer, K.; Soder, S.; Inwards, C.Y.; Bovee, J.V.; Aigner, T. Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas. Pathol. Int. 2010, 60, 365–372. [CrossRef] [PubMed]
11. Frassica, F.J.; Unni, K.K.; Beabout, J.W.; Sim, F.H. Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. J. Bone Jt. Surg. Am. 1986, 68, 1197–1205. [CrossRef] [PubMed]
12. Decker, C.; Schreuder, B.H.; Hannink, G.; de Rooy, J.W.; van der Geest, I.C. Radiologic follow-up of untreated enchondroma and atypical cartilaginous tumors in the long bones. J. Surg. Oncol. 2016, 114, 987–991. [CrossRef] [PubMed]
13. Bovee, J.V.; van den Broek, L.J.; Clifton-Jansen, A.M.; Hogendoorn, P.C. Up-regulation of pthrp and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab. Invest. 2000, 80, 1925–1934. [CrossRef] [PubMed]
14. De Andrea, C.E.; Hogendoorn, P.C. Epiphyseal growth plate and secondary peripheral chondrosarcoma: The neighbours matter. J. Pathol. 2012, 226, 219–228. [CrossRef] [PubMed]
15. Corradi, D.; Bacchini, P.; Campanini, N.; Bertoni, F. Aggressive clear cell chondrosarcomas: Do distinctive characteristics exist? A report of 4 cases. Arch. Pathol. Lab. Med. 2006, 130, 1673–1679. [PubMed]
16. Unni, K.K.; Dahlin, D.C.; Beabout, J.W.; Sim, F.H. Chondrosarcoma: Clear-cell variant. A report of sixteen cases. J. Bone Jt. Surg. Am. 1976, 58, 676–683. [CrossRef] [PubMed]
17. Nota, S.P.; Braun, V.; Schwab, J.H.; van Dijk, C.N.; Bramer, J.A. The identification of prognostic factors and survival statistics of conventional central chondrosarcoma. Sarcoma 2015, 2015, 623746. [CrossRef] [PubMed]
18. Angelini, A.; Guerra, G.; Mavrogenis, A.F.; Pala, E.; Picci, P.; Ruggieri, P. Clinical outcome of central conventional chondrosarcoma. J. Surg. Oncol. 2012, 106, 929–937. [CrossRef] [PubMed]
19. Bindiganavile, S.; Han, I.; Yun, J.Y.; Kim, H.S. Long-term outcome of chondrosarcoma: A single institutional experience. Cancer Res. Treat. 2015, 47, 897–903. [CrossRef] [PubMed]
20. Boxall, S.A.; Jones, E. Markers for characterization of bone marrow multipotent stromal cells. Stem Cells Int. 2012, 2012, 975871. [CrossRef] [PubMed]
21. David, E.; Blanchard, F.; Heymann, M.F.; De Pinieux, G.; Gouin, F.; Redini, F.; Heymann, D. The bone niche of chondrosarcoma: A sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma 2011, 2011, 932451. [CrossRef] [PubMed]
22. Fujiwara, T.; Ozaki, T. Overcoming therapeutic resistance of bone sarcomas: Overview of the molecular mechanisms and therapeutic targets for bone sarcoma stem cells. Stem Cells Int. 2016, 2016, 2603092. [CrossRef] [PubMed]
23. Diaz-Romero, J.; Romeo, S.; Bovee, J.V.; Hogendoorn, P.C.; Heini, P.F.; Mainil-Varlet, P. Hierarchical clustering of flow cytometry data for the study of conventional central chondrosarcoma. J. Cell. Physiol. 2010, 225, 601–611. [CrossRef] [PubMed]
24. Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8, 315–317. [CrossRef] [PubMed]
25. Gronthos, S.; Zannettino, A.C.; Hay, S.J.; Shi, S.; Graves, S.E.; kortesidis, A.; Simmons, P.J. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J. Cell Sci. 2003, 116, 1827–1835. [CrossRef] [PubMed]
26. Bianco, P.; Kuznetsov, S.A.; Riminucci, M.; Gehron Robey, P. Postnatal skeletal stem cells. Methods Enzymol. 2006, 419, 117–148. [PubMed]
27. Frenette, P.S.; Pinho, S.; Lucas, D.; Scheiermann, C. Mesenchymal stem cell: Keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu. Rev. Immunol. 2013, 31, 285–316. [CrossRef] [PubMed]
28. Senbanjo, L.T.; Chellaiah, M.A. CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front. Cell Dev. Biol. 2017, 5, 18. [CrossRef] [PubMed]
29. Heyse, T.J.; Malcherczyk, D.; Moll, R.; Timmesfeld, N.; Wapelhorst, J.; Fuchs-Winkelmann, S.; Paletta, J.R.; Schofer, M.D. CD44: Survival and metastasis in chondrosarcoma. Osteoarthr. Cartil. 2010, 18, 849–856. [CrossRef] [PubMed]
30. Qian, H.; Le Blanc, K.; Sigvardsson, M. Primary mesenchymal stem and progenitor cells from bone marrow lack expression of cd44 protein. J. Biol. Chem. 2012, 287, 25795–25807. [CrossRef] [PubMed]
31. Bernstein, P.; Sperling, I.; Corbeil, D.; Hempel, U.; Fickert, S. Progenitor cells from cartilage—No osteoarthritis-grade-specific differences in stem cell marker expression. Biotechnol. Prog. 2013, 29, 206–212. [CrossRef] [PubMed]
32. Alexander, D.; Schafer, F.; Munz, A.; Friedrich, B.; Klein, C.; Hoffmann, J.; Bühring, H.J.; Reinert, S. Lngfr induction during osteogenesis of human jaw periosteum-derived cells. Cell. Physiol. Biochem. 2009, 24, 283–290. [CrossRef] [PubMed]
33. Wirths, S.; Malenke, E.; Kluba, T.; Rieger, S.; Muller, M.R.; Schleicher, S.; Hann von Weyhern, C.; Nagl, F.; Fend, F.; Vogel, W.; et al. Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas. Stem Cells Transl. Med. 2013, 2, 53–60. [CrossRef] [PubMed]
34. Lefebvre, V.; Dvir-Ginzberg, M. Sox9 and the many facets of its regulation in the chondrocyte lineage. Connect. Tissue Res. 2017, 58, 2–14. [CrossRef] [PubMed]
35. Lefebvre, V.; Bhattaram, P. Soxc genes and the control of skeletogenesis. *Curr. Osteoporos. Rep.* 2016, 14, 32–38. [CrossRef] [PubMed]
36. Soderstrom, M.; Bohling, T.; Efkors, T.; Nilimarkka, L.; Aro, H.T.; Vuorio, E. Molecular profiling of human chondrosarcomas for matrix production and cancer markers. *Int. J. Cancer* 2002, 100, 144–151. [CrossRef] [PubMed]
37. Liu, C.F.; Lefebvre, V. The transcription factors SOX9 and SOX5/SOX6 cooperate genome-wide through super-enhancers to drive chondrogenesis. *Nucleic Acids Res.* 2015, 43, 8183–8203. [CrossRef] [PubMed]
38. Mak, I.W.; Singh, S.; Turcotte, R.; Ghert, M. The epigenetic regulation of sox9 by mir-145 in human chondrosarcoma. *J. Cell. Biochem.* 2015, 116, 37–44. [CrossRef] [PubMed]
39. Sekiya, I.; Vuoristo, J.T.; Larson, B.L.; Prockop, D.J. In vitro cartilage formation by human adult stem cells from bone marrow stroma defines the sequence of cellular and molecular events during chondrogenesis. *Proc. Natl. Acad. Sci. USA* 2002, 99, 4397–4402. [CrossRef] [PubMed]
40. Lu, N.; Lin, T.; Wang, L.; Qi, M.; Liu, Z.; Dong, H.; Zhang, X.; Zhai, C.; Wang, Y.; Liu, L.; et al. Association of sox4 regulated by tumor suppressor mir-30a with poor prognosis in low-grade chondrosarcoma. *Tumour Biol.* 2015, 36, 3843–3852. [CrossRef] [PubMed]
41. Zhang, P.; Li, J.; Song, Y.; Wang, X. Mir-129–5p inhibits proliferation and invasion of chondrosarcoma cells by regulating sox4/wnt/β-catenin signaling pathway. *Cell. Physiol. Biochem.* 2017, 42, 242–253. [CrossRef] [PubMed]
42. Mazor, M.; Cesaro, A.; Ali, M.; Best, T.M.; Lespessaille, E.; Toumi, H. Progenitor cells from cartilage: Grade specific differences in stem cell marker expression. *Int. J. Mol. Sci.* 2017, 18, 1759. [CrossRef] [PubMed]
43. Grogan, S.P.; Miyaki, S.; Asahara, H.; D’Lima, D.D.; Lotz, M.K. Mesenchymal progenitor cell markers in human articular cartilage: Normal distribution and changes in osteoarthritis. *Arthritis Res. Ther.* 2009, 11, R85. [CrossRef] [PubMed]
44. Jiang, Y.; Tuan, R.S. Origin and function of cartilage stem/progenitor cells in osteoarthritis. *Nat. Rev. Rheumatol.* 2015, 11, 206–212. [CrossRef] [PubMed]
45. Williams, R.; Khan, I.M.; Richardson, K.; Nelson, L.; McCarthy, H.E.; Analbelsi, T.; Singhrao, S.K.; Dowthwaite, G.P.; Jones, R.E.; Baird, D.M.; et al. Identification and clonal characterisation of a progenitor cell sub-population in normal human articular cartilage. *PLoS ONE* 2010, 5, e13246. [CrossRef] [PubMed]
46. Pretzel, D.; Linss, S.; Rochler, S.; Endres, M.; Kaps, C.; Alsalameh, S.; Kinne, R.W. Relative percentage and zonal distribution of mesenchymal progenitor cells in human osteoartritic and normal cartilage. *Arthritis Res. Ther.* 2011, 13, R64. [CrossRef] [PubMed]
47. Alsalameh, S.; Amin, R.; Gemba, T.; Lotz, M. Identification of mesenchymal progenitor cells in normal and osteoarthritis human articular cartilage. *Ann. Rheum. Dis.* 2004, 50, 1522–1532. [CrossRef] [PubMed]
48. Li, S.; Sengers, B.G.; Orefio, R.O.; Tare, R.S. Chondrogenic potential of human articular chondrocytes and skeletal stem cells: A comparative study. *J. Biomater. Appl.* 2015, 29, 824–836. [CrossRef] [PubMed]
49. Hiraoka, K.; Grogan, S.; Olee, T.; Lotz, M. Mesenchymal progenitor cells in adult human articular cartilage. *Biochimie* 2006, 88, 447–454. [PubMed]
50. Ozbey, O.; Sahin, Z.; Acar, N.; Ozcelik, F.T.; Ozenci, A.M.; Koksoy, S.; Ustunel, I. Characterization of colony-forming cells in adult human articular cartilage. *Acta Histochem.* 2014, 116, 763–770. [CrossRef] [PubMed]
51. Hoshijama, Y.; Otsuki, S.; Oda, S.; Kurokawa, Y.; Nakajima, M.; Jotoku, T.; Tamura, R.; Okamoto, Y.; Lotz, M.K.; Neo, M. Chondrocyte clusters adjacent to sites of cartilage degeneration have characteristics of progenitor cells. *J. Orthop. Res.* 2015, 33, 548–555. [CrossRef] [PubMed]
52. Fickert, S.; Fiedler, J.; Brenner, R.E. Identification of subpopulations with characteristics of mesenchymal progenitor cells from human osteoarthritic cartilage using triple staining for cell surface markers. *Arthritis Res. Ther.* 2004, 6, R422–R432. [CrossRef] [PubMed]
53. Fellows, C.R.; Williams, R.; Davies, I.R.; Gohl, K.; Baird, D.M.; Fairclough, J.; Rooney, P.; Archer, C.W.; Khan, L.M. Characterisation of a divergent progenitor cell sub-populations in human osteoarthritic cartilage: The role of telomere erosion and replicative senescence. *Sci. Rep.* 2017, 7, 41421. [CrossRef] [PubMed]
54. Solchaga, L.A.; Penick, K.; Porter, J.D.; Goldberg, V.M.; Caplan, A.I.; Welte, J.F. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. *J. Cell. Physiol.* 2005, 203, 398–409. [CrossRef] [PubMed]
55. Tsutsumi, S.; Shimazu, A.; Miyazaki, K.; Pan, H.; Koike, C.; Yoshida, E.; Takagishi, K.; Kato, Y. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem. Biophys. Res. Commun. 2001, 288, 413–419. [CrossRef] [PubMed]

56. Mastrogiacomo, M.; Cancedda, R.; Quarto, R. Effect of different growth factors on the chondrogenic potential of human bone marrow stromal cells. Osteoarthr. Cartil. 2001, 9 (Suppl. A), S36–S40. [CrossRef] [PubMed]

57. Handorf, A.M.; Li, W.J. Fibroblast growth factor-2 primes human mesenchymal stem cells for enhanced chondrogenesis. PLoS ONE 2011, 6, e22887. [CrossRef] [PubMed]

58. Dombrowski, C.; Helledie, T.; Ling, L.; Grunert, M.; Canning, C.A.; Jones, C.M.; Hui, J.H.; Nurcombe, V.; van Wijnen, A.J.; Cool, S.M. FGFR1 signaling stimulates proliferation of human mesenchymal stem cells by inhibiting the cyclin-dependent kinase inhibitors p21(Waf1) and p27(Kip1). Stem Cells 2013, 31, 2724–2736. [CrossRef] [PubMed]

59. Bianchi, G.; Banfi, A.; Mastrogiacomo, M.; Notaro, R.; Luzzatto, L.; Cancedda, R.; Quarto, R. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp. Cell Res. 2003, 287, 98–105. [CrossRef]

60. Hardingham, T.E.; Oldershaw, R.A.; Tew, S.R. Cartilage, sox9 and notch signals in chondrogenesis. J. Anat. 2006, 209, 469–480. [CrossRef] [PubMed]

61. Hurley, M.M.; Gronowicz, G.; Zhu, L.; Kuhn, L.T.; Rodner, C.; Xiao, L. Age-related changes in FGF-2, fibroblast growth factor receptors and β-catenin expression in human mesenchyme-derived progenitor cells. J. Cell. Biochem. 2016, 117, 721–729. [CrossRef] [PubMed]

62. Rolauffs, B.; Rothdiener, M.; Bahrs, C.; Badke, A.; Weise, K.; Kuettner, K.E.; Kurz, B.; Aurich, M.; Grodzinsky, A.J.; Aicher, W.K. Onset of preclinical osteoarthritis: The angular spatial organization permits early diagnosis. Arthritis Rheum. 2011, 63, 1637–1647. [CrossRef] [PubMed]

63. Rolauffs, B.; Williams, J.M.; Aurich, M.; Grodzinsky, A.J.; Kuettner, K.E.; Cole, A.A. Proliferative remodeling of the spatial organization of human superficial chondrocytes distant from focal early osteoarthritis. Arthritis Rheum. 2010, 62, 489–498. [PubMed]

64. Hsu, C.J.; Lin, T.Y.; Kuo, C.C.; Tsai, C.H.; Lin, M.Z.; Hsu, H.C.; Fong, Y.C.; Tang, C.H. Involvement of integrin up-regulation in rankl/rank pathway of chondrosarcomas migration. J. Cell. Biochem. 2010, 111, 138–147. [CrossRef] [PubMed]

65. McGough, R.L.; Lin, C.; Meitner, P.; Aswad, B.I.; Terek, R.M. Angiogenic cytokines in cartilage tumors. Clin. Orthop. Relat. Res. 2002, 62–69. [CrossRef] [PubMed]

66. Cintra, F.F.; Etchebehere, M.; Goncalves, J.C.; Cassone, A.E.; Amstalden, E.M. Vascular pattern in enchondroma and chondrosarcoma: Clinical and immunohistologic study. Appl. Immunohistochem. Mol. Morphol. 2014, 22, 600–605. [CrossRef] [PubMed]

67. Kalinski, T.; Sel, S.; Kouznetsova, I.; Ropke, M.; Roessner, A. Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors. Pathol. Res. Pract. 2009, 205, 339–345. [CrossRef] [PubMed]

68. Ayala, G.; Liu, C.; Nicosia, R.; Horowitz, S.; Lackman, R. Microvasculature and VEGF expression in cartilaginous tumors. Hum. Pathol. 2000, 31, 341–346. [CrossRef] [PubMed]

69. Wu, M.H.; Huang, C.Y.; Lin, J.A.; Wang, S.W.; Peng, C.Y.; Cheng, H.C.; Tang, C.H. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene 2014, 33, 1725–1735. [CrossRef] [PubMed]

70. Kalinski, T.; Krueger, S.; Sel, S.; Werner, K.; Ropke, M.; Roessner, A. Differential expression of VEGF-a and angiopoietins in cartilage tumors and regulation by interleukin-1β. Cancer 2006, 106, 2028–2038. [CrossRef] [PubMed]

71. Papachristou, D.J.; Papachristou, G.I.; Papaefthimiou, O.A.; Agnantis, N.J.; Basdra, E.K.; Papavassiliou, A.G. The mapk-ap-1/-runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology 2005, 47, 565–574. [CrossRef] [PubMed]

72. Uria, J.A.; Balbin, M.; Lopez, J.M.; Alvarez, J.; Vizoso, F.; Takigawa, M.; Lopez-Otin, C. Collagenase-3 (mmp-13) expression in chondrosarcoma cells and its regulation by basic fibroblast growth factor. Am. J. Pathol. 1998, 153, 91–101. [CrossRef] [PubMed]

73. Chen, C.; Zhou, H.; Wei, F.; Jiang, L.; Liu, X.; Liu, Z.; Ma, Q. Increased levels of hypoxia-inducible factor-1α are associated with bcl-xl expression, tumor apoptosis, and clinical outcome in chondrosarcoma. J. Orthop. Res. 2011, 29, 143–151. [CrossRef] [PubMed]
74. Kubo, T.; Sugita, T.; Shimose, S.; Matsuo, T.; Arihiro, K.; Ochi, M. Expression of hypoxia-inducible factor-1α and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J. Bone Jt. Surg. Br. 2008, 90, 364–370. [CrossRef] [PubMed]

75. Presta, M.; Andres, G.; Leali, D.; Dell’Era, P.; Ronca, R. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur. Cytokine Netw. 2009, 20, 39–50. [PubMed]

76. Liao, Y.X.; Zhou, C.H.; Zeng, H.; Zuo, D.Q.; Wang, Z.Y.; Yin, F.; Hua, Y.Q.; Cai, Z.D. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (review). Int. J. Mol. Med. 2013, 32, 1239–1246. [CrossRef] [PubMed]

77. Bai, S.; Wang, D.; Klein, M.J.; Siegal, G.P. Characterization of CXCR4 expression in chondrosarcoma of bone. Arch. Pathol. Lab. Med. 2011, 135, 753–758. [PubMed]

78. Sun, X.; Wei, L.; Chen, Q.; Terek, R.M. MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells. Clin. Orthop. Relat. Res. 2015, 473, 907–913. [CrossRef] [PubMed]

79. Sun, X.; Wei, L.; Chen, Q.; Terek, R.M. CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through erk signaling and increased mmp1 expression. Mol. Cancer 2010, 9, 17. [CrossRef] [PubMed]

80. Sun, X.; Charbonneau, C.; Wei, L.; Yang, W.; Chen, Q.; Terek, R.M. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis. Mol. Cancer Ther. 2013, 12, 1163–1170. [CrossRef] [PubMed]

81. Liu, G.T.; Huang, Y.L.; Tzeng, H.E.; Tsai, C.H.; Wang, S.W.; Tang, C.H. Ccl5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating mir-199a in human chondrosarcoma cells. Cancer Lett. 2015, 357, 476–487. [CrossRef] [PubMed]

82. Tzeng, H.E.; Chang, A.C.; Tsai, C.H.; Wang, S.W.; Tang, C.H. Basic fibroblast growth factor promotes VEGF-C-dependent lymphangiogenesis via inhibition of mir-381 in human chondrosarcoma cells. Oncotarget 2016, 7, 38566–38578. [CrossRef] [PubMed]

83. Inoki, I.; Shiomi, T.; Hashimoto, G.; Enomoto, H.; Nakamura, H.; Makino, K.; Ikeda, E.; Takata, S.; Kobayashi, K.; Okada, Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002, 16, 219–221. [CrossRef] [PubMed]

84. Hashimoto, G.; Inoki, I.; Fujiy, Y.; Aoki, T.; Ikeda, E.; Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem. 2002, 277, 36288–36295. [CrossRef] [PubMed]

85. Yu, C.; Le, A.T.; Yeger, H.; Perbal, B.; Alman, B.A. Nov (ccn3) regulation in the growth plate and ccn family member expression in cartilage neoplasia. J. Pathol. 2003, 201, 609–615. [CrossRef] [PubMed]

86. Lin, C.Y.; Tzeng, H.E.; Li, T.M.; Chen, H.T.; Lee, Y.; Wang, S.W.; Tang, C.H. Wisp-3 inhibition of mir-452 promotes VEGF-a expression in chondrosarcoma cells and reduces endothelial progenitor cells angiogenesis. Oncotarget 2017, 8, 39571–39581. [CrossRef] [PubMed]

87. Wang, Z.; Bryan, J.; Franz, C.; Havlioglu, N.; Sandell, L.J. Type IIIB procollagen NH(2)-propeptide induces death of tumor cells via interaction with integrins α(v)β(3) and α(v)β(5). J. Biol. Chem. 2010, 285, 20806–20817. [CrossRef] [PubMed]

88. Salter, D.M.; Hughes, D.E.; Simpson, R.; Gardner, D.L. Integrin expression by human articular chondrocytes. Br. J. Rheumatol. 1992, 31, 231–234. [CrossRef] [PubMed]

89. Teitelbaum, S.L. Osteoclasts, integrins, and osteoporosis. J. Bone Miner. Metab. 2000, 18, 344–349. [CrossRef] [PubMed]

90. Chereshe, D.A.; Stupack, D.G. Integrin-mediated death: An explanation of the integrin-knockout phenotype? Nat. Med. 2002, 8, 193–194. [CrossRef] [PubMed]

91. Jablonska-Trypuc, A.; Matejczyk, M.; Rosochacki, S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J. Enzyme Inhib. Med. Chem. 2016, 31, 177–183. [CrossRef] [PubMed]

92. Kessenbrock, K.; Wang, C.Y.; Werb, Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 2015, 44–46, 184–190. [CrossRef] [PubMed]

93. Rodier, F.; Campisi, J. Four faces of cellular senescence. J. Cell Biol. 2011, 192, 547–556. [CrossRef] [PubMed]

94. Nissinen, L.; Kahari, V.M. Matrix metalloproteinases in inflammation. Biochim. Biophys. Acta 2014, 1840, 2571–2580. [CrossRef] [PubMed]
95. Kawashima, A.; Okada, Y.; Nakanishi, I.; Ueda, Y.; Iwata, K.; Roessner, A. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. *Gen. Diagn. Pathol.* 1997, 142, 129–137. [PubMed]

96. Schwab, J.H.; Boland, P.J.; Agaram, N.P.; Socci, N.D.; Guo, T.; O’Toole, G.C.; Wang, X.; Ostrowoum, E.; Hunter, C.J.; Block, J.A.; et al. Chordoma and chondrosarcoma gene profile: Implications for immunotherapy. *Cancer Immunol. Immunother.* 2009, 58, 339–349. [CrossRef] [PubMed]

97. Xu, X.; Ma, J.; Li, C.; Zhao, W.; Xu, Y. Regulation of chondrosarcoma invasion by MMP26. *Tumour Biol.* 2015, 36, 365–369. [CrossRef] [PubMed]

98. Jiang, X.; Dutton, C.M.; Qi, W.N.; Block, J.A.; Garamszegi, N.; Scully, S.P. Sirna mediated inhibition of mmp-1 reduces invasive potential of a human chondrosarcoma cell line. *J. Cell. Physiol.* 2005, 202, 723–730. [CrossRef] [PubMed]

99. Dickey, I.D.; Scully, S.P. Identification of a single nucleotide polymorphism in the MMP-1 promoter in chondrosarcoma. *J. Surg. Oncol.* 2004, 87, 130–133. [CrossRef] [PubMed]

100. Fong, Y.C.; Dutton, C.M.; Cha, S.S.; Garamszegi, N.; Sim, F.H.; Scully, S.P. Absence of a correlation between the presence of a single nucleotide polymorphism in the matrix metalloproteinase I promoter and outcome in patients of chondrosarcoma. *Clin. Cancer Res.* 2004, 10, 7329–7334. [CrossRef] [PubMed]

101. Boeuf, S.; Bovee, J.V.; Lehner, B.; Hogendoorn, P.C.; Richter, W. Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. *Histopathology* 2010, 56, 641–651. [CrossRef] [PubMed]

102. Hsu, C.J.; Wu, M.H.; Chen, C.Y.; Tsai, C.H.; Hsu, H.C.; Tang, C.H. Amp-activated protein kinase activation mediates ccl3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma. *Cell Commun. Signal.* 2013, 11, 68. [CrossRef] [PubMed]

103. Sugita, H.; Osaka, S.; Toriyama, M.; Osaka, E.; Yoshida, Y.; Ryu, J.; Sano, M.; Sugitani, M.; Nemoto, N. Correlation between the histological grade of chondrosarcoma and the expression of mmps, adamtss and temps. *Anticancer Res.* 2004, 24, 4079–4084. [PubMed]

104. Soderstrom, M.; Aro, H.T.; Ahonen, M.; Johansson, N.; Aho, A.; Ekkors, T.; Bohling, T.; Kahari, V.M.; Vuorio, E. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. *APMIS* 2001, 109, 305–315. [CrossRef] [PubMed]

105. Tang, C.H.; Yamamoto, A.; Lin, Y.T.; Fong, Y.C.; Tan, T.W. Involvement of matrix metalloproteinase-3 in ccl5/ccr5 pathway of chondrosarcomas metastasis. *Biochem. Pharmacol.* 2010, 79, 209–217. [CrossRef] [PubMed]

106. Doerstling, S.S.; O’Flanagan, C.H.; Hursting, S.D. Obesity and cancer metabolism: A perspective on interacting tumor-intrinsic and extrinsic factors. *Front. Oncol.* 2017, 7, 216. [CrossRef] [PubMed]

107. Yang, R.Z.; Huang, Q.; Xu, A.; McLenithan, J.C.; Eisen, J.A.; ShULDINER, A.R.; Alkan, S.; Gong, D.W. Comparative studies of resistin expression and phylogenomics in human and mouse. *Biochem. Biophys. Res. Commun.* 2003, 310, 927–935. [CrossRef] [PubMed]

108. Tsai, C.H.; Tsai, H.C.; Huang, H.N.; Hung, C.H.; Hsu, C.J.; Fong, Y.C.; Hsu, H.C.; Huang, Y.L.; Tang, C.H. Resistin promotes tumor metastasis by down-regulation of mir-519d through the ampk/p38 signaling pathway in human chondrosarcoma cells. *Oncotarget* 2015, 6, 258–270. [CrossRef] [PubMed]

109. Lee, H.P.; Lin, C.Y.; Shih, J.S.; Fong, Y.C.; Wang, S.W.; Li, T.M.; Tang, C.H. Adiponectin promotes VEGF-A-dependent angiogenesis in human chondrosarcoma through pi3k, akt, mtor, and hif-α pathway. *Oncotarget* 2015, 6, 36746–36761. [CrossRef] [PubMed]

110. Chiu, Y.C.; Shieh, D.C.; Tong, K.M.; Chen, C.P.; Huang, K.C.; Chen, P.C.; Fong, Y.C.; Hsu, H.C.; Tang, C.H. Involvement of adipor receptor in adiponectin-induced motility and αβ1 integrin upregulation in human chondrosarcoma cells. *Carcinogenesis* 2009, 30, 1651–1659. [CrossRef] [PubMed]

111. Shinagawa, S.; Okazaki, T.; Ikeda, M.; Yudoh, K.; KISANUKI, Y.Y.; Yanagisawa, M.; Kawahata, K.; Ozaki, S. T cells upon activation promote endothelin 1 production in monocytes via ifn-gamma and trnf-α. *Sci. Rep.* 2017, 7, 14500. [CrossRef] [PubMed]

112. Patrignani, P.; Tacconelli, S.; Scuilli, M.G.; Capone, M.L. New insights into cox-2 biology and inhibition. *Brain Res. Brain Res. Rev.* 2005, 48, 352–359. [CrossRef] [PubMed]

113. Castello, L.M.; Raineri, D.; Salmi, L.; Clemente, N.; Vaschetto, R.; Quaglia, M.; Garzaro, M.; Gentilli, S.; Navalesi, P.; Cantaluppi, V.; et al. Osteopontin at the crossroads of inflammation and tumor progression. *Mediat. Inflamm.* 2017, 2017, 4049098. [CrossRef] [PubMed]
114. Wei, R.; Wong, J.P.C.; Kwok, H.F. Osteopontin—a promising biomarker for cancer therapy. J. Cancer 2017, 8, 2173–2183. [CrossRef] [PubMed]

115. Leali, D.; Dell’Era, P.; Stabile, H.; Sennino, B.; Chambers, A.F.; Naldini, A.; Sozzani, S.; Nico, B.; Ribatti, D.; Presta, M. Osteopontin (eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J. Immunol. 2003, 171, 1085–1093. [CrossRef] [PubMed]

116. Chen, Y.J.; Wei, Y.Y.; Chen, H.T.; Fong, Y.C.; Hsu, C.J.; Tsai, C.H.; Hsu, H.C.; Liu, S.H.; Tang, C.H. Osteopontin increases migration and mmp-9 up-regulation via avβ3 integrin, fak, erk, and NF-kb-dependent pathway in human chondrosarcomas. J. Cell. Physiol. 2009, 221, 98–108. [CrossRef] [PubMed]

117. Tan, T.W.; Lai, C.H.; Huang, C.Y.; Wang, L.; Welter, J.F.; Ballock, R.T. Primary cilia modulate ihh signal transduction in response to dynamic compression regulates the expression and synthesis of chondrocyte-specific matrix molecules in bone marrow stromal cells. Stem Cells Dev. 2007, 16, 655–663. [CrossRef] [PubMed]

118. Pelaez, D.; Huang, C.Y.; Cheung, H.S. Cyclic compression maintains viability and induces chondrogenesis of human mesenchymal stem cells in fibrin gel scaffolds. Stem Cells Dev. 2009, 18, 93–102. [CrossRef] [PubMed]

119. Kouri, J.B.; Jimenez, S.A.; Quintero, M.; Chico, A. Ultrastructural study of chondrocytes from fibrillated and non-fibrillated human osteoarthritic cartilage. Osteoarthr. Cartil. 1996, 4, 111–125. [CrossRef]

120. Guan, X. Cancer metastases: Challenges and opportunities. Acta Pharm. Sin. B 2015, 5, 402–418. [CrossRef] [PubMed]

121. Shao, Y.Y.; Wang, L.; Welter, J.F.; Ballock, R.T. Primary cilia modulate ihh signal transduction in response to hydrostatic loading of growth plate chondrocytes. Bone 2012, 50, 79–84. [CrossRef] [PubMed]

122. Thompson, C.L.; Chapple, J.P.; Knight, M.M. Primary cilia disassembly down-regulates mechanosensitive hedgehog signalling: A feedback mechanism controlling adams-5 expression in chondrocytes. Osteoarthr. Cartil. 2014, 22, 490–498. [CrossRef] [PubMed]

123. McGlashan, S.R.; Cluett, E.C.; Jensen, C.G.; Poole, C.A. Primary cilia in osteoarthritic chondrocytes: From polarization to polarity in the growth plate and implies loss of polarity and mosaicism in osteochondroma. Lab. Investig. 2010, 90, 1091–1101. [CrossRef] [PubMed]
135. Bovee, J.V.; Hogendoorn, P.C.; Wunder, J.S.; Alman, B.A. Cartilage tumours and bone development: Molecular pathology and possible therapeutic targets. *Nat. Rev. Cancer* 2010, 10, 481–488. [CrossRef] [PubMed]

136. Hickey, M.; Farrokhyar, F.; Deheshi, B.; Turcotte, R.; Ghert, M. A systematic review and meta-analysis of intralesional versus wide resection for intramedullary grade i chondrosarcoma of the extremities. *Ann. Surg. Oncol.* 2011, 18, 1705–1709. [CrossRef] [PubMed]

137. David, E.; Guihard, P.; Brounais, A.; Cionetti, S.; Piperno-Neumann, S.; Meijer, D.; Briaire-de Bruijn, I.H.; Cleton-Jansen, A.M.; Gelderblom, H.; van Oosterwijk, J.G.; Herpers, B.; Bovee, J.V.; Cleton-Jansen, A.M.; Taminiau, A.H.; Hogendoorn, P.C. Emerging pathways in the development of chondrosarcoma of bone: An assessment of outcome. *J. Bone Jt. Surg. Am.* 1999, 81, 326–338. [CrossRef] [PubMed]

138. Onishi, A.C.; Hincker, A.M.; Lee, F.Y.; Mankin, H.J.; Fondren, G.; Gebhardt, M.C.; Springfield, D.S.; Rosenberg, A.E.; Jennings, L.C. Intrinsic resistance in human chondrosarcoma cells. *Biochem. Biophys. Res. Commun.* 2006, 346, 379–385. [CrossRef] [PubMed]

139. Terek, R.M.; Schwartz, G.K.; Devaney, K.; Glantz, L.; Mak, S.; Healey, J.H.; Albino, A.P. Chemotherapy and p-glycoprotein expression in chondrosarcoma. *J. Orthop. Res.* 1998, 16, 585–590. [CrossRef] [PubMed]

140. Mitchell, A.D.; Ayoub, K.; Mangham, D.C.; Grimer, R.J.; Carter, S.R.; Tillman, R.M. Experience in the treatment of dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes. *J. Bone Jt. Surg. Br.* 2000, 82, 55–61. [CrossRef] [PubMed]

141. Moussavi-Harami, F.; Mollano, A.; Martin, J.A.; Ayoub, A.; Domann, F.E.; Gitelis, S.; Buckwalter, J.A. Intrinsic signaling pathway and the potential for treatment advancement in sarcoma. *Pharmacol. Ther.* 2012, 81, 227–237. [CrossRef] [PubMed]

142. Outani, H.; Hamada, K.; Imura, Y.; Oshima, K.; Sotobori, T.; Demizu, Y.; Kakunaga, S.; Joyama, S.; Imai, R.; Okamoto, T.; et al. Comparison of clinical and functional outcome between surgical treatment and carbon ion radiotherapy for pelvic chondrosarcoma. *Int. J. Clin. Oncol.* 2016, 21, 186–193. [CrossRef] [PubMed]

143. Bovee, J.V.; Cleton-Jansen, A.M.; Taminiau, A.H.; Hogendoorn, P.C. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma of the extremities in vitro: Role of p-glycoprotein expression. *Br. J. Cancer.* 2011, 104, 1705–1711. [CrossRef] [PubMed]

144. Dickey, I.D.; Rose, P.S.; Fuchs, B.; Wold, L.E.; Okuno, S.H.; Sim, F.H.; Scully, S.P. Dedifferentiated chondrosarcoma: Gene expression profile and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. *Genes Chromosom. Cancer* 1999, 26, 237–246. [CrossRef] [PubMed]

145. Tallini, G.; Dorfman, H.; Brys, P.; Dal Cin, P.; De Wever, I.; Fletcher, C.D.; Jonson, K.; Mandahl, N.; Mertens, F.; Mitelman, F.; et al. Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours. A report from the chromosomes and morphology (champ) collaborative study group. *J. Pathol.* 2002, 196, 194–203. [CrossRef] [PubMed]

146. Kelleher, F.C.; Cain, J.E.; Healy, J.M.; Watkins, D.N.; Thomas, D.M. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. *Pharmacol. Ther.* 2012, 136, 153–168. [CrossRef] [PubMed]
154. Amakye, D.; Jagani, Z.; Dorsch, M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. *Nat. Med.* **2013**, *19*, 1410–1422. [CrossRef] [PubMed]

155. Petrova, R.; Joyner, A.L. Roles for hedgehog signaling in adult organ homeostasis and repair. *Development* **2014**, *141*, 3445–3457. [CrossRef] [PubMed]

156. Merchant, A.A.; Matsui, W. Targeting hedgehog—a cancer stem cell pathway. *Clin. Cancer Res.* **2010**, *16*, 3130–3140. [CrossRef] [PubMed]

157. Boehme, K.A.; Zaborski, J.J.; Riester, R.; Schweiss, S.K.; Hopp, U.; Traub, F.; Kluba, T.; Handgretinger, R.; Schleicher, S.B. Targeting hedgehog signalling by arsenic trioxide reduces cell growth and induces apoptosis in rhabdomyosarcoma. *Int. J. Oncol.* **2016**, *48*, 801–812. [CrossRef] [PubMed]

158. Aberger, F.; Kern, D.; Greil, R.; Hartmann, T.N. Canonical and noncanonical hedgehog/gli signaling in hematological malignancies. *Vitam. Horm.* **2012**, *88*, 25–54. [PubMed]

159. Yan, T.; Angelini, M.; Alman, B.A.; Andrulis, I.L.; Wunder, J.S. Patched-one or smoothened gene mutations are infrequent in chondrosarcoma. *Clin. Orthop. Relat. Res.* **2008**, *466*, 2184–2189. [CrossRef] [PubMed]

160. Tiet, T.D.; Hopyan, S.; Nadesan, P.; Gokgoz, N.; Poon, R.; Lin, A.C.; Yan, T.; Andrulis, I.L.; Alman, B.A.; Wunder, J.S. Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. *Am. J. Pathol.* **2006**, *168*, 321–330. [CrossRef] [PubMed]

161. Schrage, Y.M.; Hameetman, L.; Szuhaï, K.; Cleton-Jansen, A.M.; Taminiau, A.H.; Hogendoorn, P.C.; Bovee, J.V. Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. *Am. J. Pathol.* **2009**, *174*, 979–988. [CrossRef] [PubMed]

162. Hameetman, L.; Rozeman, L.B.; Lombaerts, M.; Oosting, J.; Taminiau, A.H.; Cleton-Jansen, A.M.; Bovee, J.V.; Hogendoorn, P.C. Peripheral chondrosarcoma progression is accompanied by increased indigohedgehog signalling. *J. Pathol.* **2006**, *209*, 501–511. [CrossRef] [PubMed]

163. Caparros-Martin, J.A.; Valencia, M.; Reytor, E.; Pacheco, M.; Fernandez, M.; Perez-Aytes, A.; Gean, E.; Lapunzina, P.; Peters, H.; Goodship, J.A.; et al. The ciliary evc/evc2 complex interacts with smo and controls hedgehog pathway activity in chondrocytes by regulating sufu/gli3 dissociation and gli3 trafficking in primary cilia. *Hum. Mol. Genet.* **2013**, *22*, 124–139. [CrossRef] [PubMed]

164. Italiano, A.; Le Cesne, A.; Bellera, C.; Piperno-Neumann, S.; Duffaud, F.; Penel, N.; Cassier, P.; Domont, J.; Takebe, N.; Kind, M.; et al. Gdc-0449 in patients with advanced chondrosarcomas: A french sarcoma group/us and french national cancer institute single-arm phase ii collaborative study. *Ann. Oncol.* **2013**, *24*, 2922–2926. [CrossRef] [PubMed]

165. Xiang, W.; Jiang, T.; Guo, F.; Gong, C.; Yang, K.; Wu, Y.; Huang, X.; Cheng, W.; Xu, K. Hedgehog pathway inhibitor-4 suppresses malignant properties of chondrosarcoma cells by disturbing tumor ciliogenesis. *Oncol. Rep.* **2014**, *32*, 1622–1630. [CrossRef] [PubMed]

166. Jiao, G.; Ren, T.; Guo, W.; Ren, C.; Yang, K. Arsenic trioxide inhibits growth of human chondrosarcoma cells through g2/m arrest and apoptosis as well as autophagy. *Tumour Biol.* **2015**, *36*, 3969–3977. [CrossRef] [PubMed]

167. Clark, O.; Yen, K.; Mellinghoff, I.K. Molecular pathways: Isocitrate dehydrogenase mutations in cancer. *Clin. Cancer Res.* **2016**, *22*, 1837–1842. [CrossRef] [PubMed]

168. Hirata, M.; Sasaki, M.; Cairns, R.A.; Inoue, S.; Puvivindran, V.; Li, W.Y.; Snow, B.E.; Jones, L.D.; Wei, Q.; Sato, S.; et al. Mutant idh is sufficient to initiate enchondromatosis in mice. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 2829–2834. [CrossRef] [PubMed]

169. Pansuriya, T.C.; van Eijk, R.; d’Adamo, P.; van Ruler, M.A.; Kuijjer, M.L.; Oosting, J.; Cleton-Jansen, A.M.; van Oosterwijk, J.G.; Verbeke, S.L.; Meijer, D.; et al. Somatic mosaic idh1 and idh2 mutations are associated with enchondroma and spindle cell hemangioma in olier disease and maffucci syndrome. *Nat. Genet.* **2011**, *43*, 1256–1261. [CrossRef] [PubMed]

170. Amary, M.F.; Bacsi, K.; Maggiani, F.; Damato, S.; Halai, D.; Berisha, F.; Pollock, R.; O’Donnell, P.; Grigoriadis, A.; Diss, T.; et al. Idh1 and idh2 mutations are frequent events in central chondrosarcoma and central and peristeal chondromas but not in other mesenchymal tumours. *J. Pathol.* **2011**, *224*, 334–343. [CrossRef] [PubMed]

171. Amary, M.F.; Ye, H.; Forbes, G.; Damato, S.; Maggiani, F.; Pollock, R.; Tirabosco, R.; Flanagan, A.M. Isocitrate dehydrogenase 1 mutations (idh1) and p16/cdkn2a copy number change in conventional chondrosarcomas. *Virchows Arch.* **2015**, *466*, 217–222. [CrossRef] [PubMed]
172. Cairns, R.A.; Mak, T.W. Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. *Cancer Discov.* 2013, 3, 730–741. [CrossRef] [PubMed]

173. Lu, C.; Ward, P.S.; Kapoor, G.S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C.R.; Khanin, R.; Figueroa, M.E.; Melnick, A.; et al. Idh mutation impairs histone demethylation and results in a block to cell differentiation. *Nature* 2012, 483, 474–478. [CrossRef] [PubMed]

174. Sasaki, M.; Knobbe, C.B.; Itsumi, M.; Elia, A.J.; Harris, I.S.; Chio, Il; Cairns, R.A.; McCracken, S.; Wakeham, A.; Haight, J.; et al. D-2-hydroxyglutarate produced by mutant idh1 perturbs collagen maturation and basement membrane function. *Genes Dev.* 2012, 26, 2038–2049. [CrossRef] [PubMed]

175. Jin, Y.; Elalaf, H.; Watanabe, M.; Tamaki, S.; Hineno, S.; Matsunaga, K.; Wolfrjen, K.; Kobayashi, Y.; Nagata, S.; Ikeya, M.; et al. Mutant idh1 dysregulates the differentiation of mesenchymal stem cells in association with gene-specific histone modifications to cartilage- and bone-related genes. *PLoS ONE* 2015, 10, e0131998. [CrossRef] [PubMed]

176. Li, L.; Paz, A.C.; Wilky, B.A.; Johnson, B.; Galoian, K.; Rosenberg, A.; Hu, G.; Tinoco, G.; Bodamer, O.; Trent, J.C. Treatment with a small molecule mutant idh1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma cells. *PLoS ONE* 2015, 10, e0133813. [CrossRef] [PubMed]

177. Molenaar, R.J.; Coelen, R.J.; Khurshed, M.; Roos, E.; Caan, M.W.; van Linde, M.E.; Kouwenhoven, M.; Bramer, J.A.; Bovee, J.V.; Mathot, R.A.; et al. Study protocol of a phase ib/ii clinical trial of metformin and chloroquine in patients with idh1-mutated or idh2-mutated solid tumours. *BMJ Open* 2017, 7, e014961. [CrossRef] [PubMed]

178. Ververis, K.; Hiong, A.; Karagiannis, T.C.; Licciardi, P.V. Histone deacetylase inhibitors (hdacis): Multitargeted anticancer agents. *Biologics* 2013, 7, 47–60. [PubMed]

179. Sakimura, R.; Tanaka, K.; Yamamoto, S.; Matsunobu, T.; Li, X.; Hanada, M.; Okada, T.; Nakamura, T.; Li, Y.; Iwamoto, Y. The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. *Clin. Cancer Res.* 2007, 13, 275–282. [CrossRef] [PubMed]

180. Wang, W.; Yu, Y.; Hao, J.; Wen, Y.; Han, J.; Hou, W.; Liu, R.; Zhao, B.; He, A.; Li, P.; et al. Genome-wide DNA methylation profiling of articular cartilage reveals significant epigenetic alterations in kashin-beck disease and osteoarthritis. *Osteoarthr. Cartil.* 2017, 25, 2127–2133. [CrossRef] [PubMed]

181. Steinberg, J.; Ritchie, G.R.S.; Roumeliotis, T.I.; Jayasuriya, R.L.; Clark, M.J.; Brooks, R.A.; Binch, A.L.A.; Shah, K.M.; Coyle, R.; Pardo, M.; et al. Integrative epigenomics, transcriptomics and proteomics of patient chondrocytes reveal genes and pathways involved in osteoarthritis. *Sci. Rep.* 2017, 7, 8935. [CrossRef] [PubMed]

182. Haseeb, A.; Makki, M.S.; Haqqi, T.M. Modulation of ten-eleven translocation 1 (tet1), isocitrate dehydrogenase (idh), α-ketoglutarate (α-kg), and DNA hydroxymethylation levels by interleukin-1β in primary human chondrocytes. *J. Biol. Chem.* 2014, 289, 6877–6885. [CrossRef] [PubMed]

183. Schrage, Y.M.; Briaire-de Bruijn, I.H.; de Miranda, N.F.; van Oosterwijk, J.; Taminiau, A.H.; van Wezel, T.; Hogendoorn, P.C.; Bovee, J.V. Kinome profiling of chondrosarcoma reveals src-pathway activity and dasatinib as option for treatment. *Cancer Res.* 2009, 69, 6216–6222. [CrossRef] [PubMed]

184. Jang, J.H.; Chung, C.P. Tenascin-c promotes cell survival by activation of akt in human chondrosarcoma cell. *Cancer Lett.* 2005, 229, 101–105. [CrossRef] [PubMed]

185. Chen, J.C.; Fong, Y.C.; Tang, C.H. Novel strategies for the treatment of chondrosarcomas: Targeting integrins. *Biomed. Res. Int.* 2013, 2013, 396839. [CrossRef] [PubMed]

186. Zhang, Y.X.; van Oosterwijk, J.G.; Sicinska, E.; Moss, S.; Remillard, S.P.; van Wezel, T.; Buhnemann, C.; Hassan, A.B.; Demetri, G.D.; Bovee, J.V.; et al. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. *Clin. Cancer Res.* 2013, 19, 3796–3807. [CrossRef] [PubMed]

187. Lin, C.; Meitner, P.A.; Terek, R.M. Pten mutation is rare in chondrosarcoma. *Diagn. Mol. Pathol.* 2002, 11, 22–26. [CrossRef] [PubMed]

188. Peterse, E.F.; Cleven, A.H.; De Jong, Y.; Briaire-de Bruijn, I.; Fletcher, J.A.; Danen, E.H.; Clelon-Jansen, A.M.; Bovee, J.V. No preclinical rationale for igf1r directed therapy in chondrosarcoma of bone. *BMC Cancer* 2016, 16, 475. [CrossRef] [PubMed]
199. Grignani, G.; Palmerini, E.; Stacchiotti, S.; Boglione, A.; Ferraresi, V.; Frustaci, S.; Comandone, A.; Casali, P.G.; Perez, J.; Decouvelaere, A.V.; Briaire-de Bruijn, I.H.; Herpers, B.; Gelderblom, H.; van de Water, B.; Bovee, J.V. Src kinases in chondrosarcoma chemoresistance and migration: Dasatinib sensitises to doxorubicin in tp53 mutant cells. Br. J. Cancer 2013, 109, 1214–1222. [CrossRef] [PubMed]

200. Sassi, N.; Laadhar, L.; Allouche, M.; Achek, A.; Kallel-Sellami, M.; Makni, S.; Sellami, S. Wnt signaling and lung adenocarcinoma transcript 1 promotes the proliferation of chondrosarcoma cell via activating notch-1 signaling pathway. Onco Targets Ther. 2014, 7, 71–72. [CrossRef] [PubMed]

201. Chen, C.; Zhou, H.; Zhang, X.; Ma, X.; Liu, Z.; Liu, X. Elevated levels of dickkopf-1 are associated with β-catenin accumulation and poor prognosis in patients with chondrosarcoma. PLoS ONE 2014, 9, e105414. [CrossRef] [PubMed]

202. Shor, A.C.; Keschman, E.A.; Lee, F.Y.; Muro-Cacho, C.; Letson, G.D.; Trent, J.C.; Pledger, W.J.; Jove, R. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on src kinase for survival. Cancer Res. 2007, 67, 2800–2808. [CrossRef] [PubMed]

203. Schuetze, S.M.; Withen, J.K.; Lucas, D.R.; Choy, E.; Samuels, B.L.; Staddon, A.P.; Lanjoo, K.N.; von Mehren, M.; Chow, W.A.; Loeb, D.M.; et al. Sarc009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer 2016, 122, 686–874. [CrossRef] [PubMed]

204. Liu, P.; Shen, J.K.; Hornicek, F.J.; Liu, F.; Duan, Z. Wnt inhibitory factor 1 (wif1) methylation and its association with clinical prognosis in patients with chondrosarcoma. Sci. Rep. 2017, 7, 1580. [CrossRef] [PubMed]

205. Siar, C.H.; Ha, K.O.; Aung, L.O.; Nakano, K.; Tsujigiwa, H.; Nagatsuksa, H.; Ng, K.H.; Kawakami, T. Immunolocalization of notch signaling protein molecules in a maxillary chondrosarcoma and its recurrent tumor. Eur. J. Med. Res. 2010, 15, 456–460. [PubMed]

206. Xu, F.; Zhang, Z.Q.; Fang, Y.C.; Li, X.L.; Sun, Y.; Xiong, C.Z.; Yan, L.Q.; Wang, Q. Metastasis-associated lung adenocarcinoma transcript 1 promotes the proliferation of chondrosarcoma cell via activating notch-1 signaling pathway. Onco Targets Ther. 2016, 9, 2143–2151. [PubMed]
207. Schrage, Y.M.; Lam, S.; Jochemsen, A.G.; Cleton-Jansen, A.M.; Taminiau, A.H.; Hogendoorn, P.C.; Bovee, J.V. Central chondrosarcoma progression is associated with prb pathway alterations: Cdk4 down-regulation and p16 overexpression inhibit cell growth in vitro. *J. Cell. Mol. Med.* 2009, 13, 2843–2852. [CrossRef] [PubMed]

208. van Beerendonk, H.M.; Rozeman, L.B.; Taminiau, A.H.; Sciot, R.; Bovee, J.V.; Cleton-Jansen, A.M.; Hogendoorn, P.C. Molecular analysis of the ink4a/ink4a-arf gene locus in conventional (central) chondrosarcomas and enchondromas: Indication of an important gene for tumour progression. *J. Pathol.* 2004, 202, 359–366. [CrossRef] [PubMed]

209. Asp, J.; Inerot, S.; Block, J.A.; Lindahl, A. Alterations in the regulatory pathway involving p16, prb and cdk4 in human chondrosarcoma. *J. Orthop. Res.* 2001, 19, 149–154. [CrossRef]

210. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune checkpoint blockade: A common denominator approach to cancer therapy. *Cancer Cell* 2015, 27, 450–461. [CrossRef] [PubMed]

211. Yoshitaka, T.; Kawai, A.; Miyaki, S.; Numoto, K.; Kikuta, K.; Ozaki, T.; Lotz, M.; Asahara, H. Analysis of microRNAs expressions in chondrosarcoma. *J. Orthop. Res.* 2013, 31, 1992–1998. [CrossRef] [PubMed]

212. Zhu, Z.; Wang, C.P.; Zhang, Y.F.; Nie, L. MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mtor. *Asian Pac. J. Cancer Prev.* 2014, 15, 917–923. [CrossRef] [PubMed]

213. Tang, X.Y.; Zheng, W.; Ding, M.; Guo, K.J.; Yuan, F.; Feng, H.; Deng, B.; Sun, W.; Hou, Y.; Gao, L. Mir-125b acts as a tumor suppressor in chondrosarcoma cells by the sensitization to doxorubicin through direct targeting the erbb2-regulated glucose metabolism. *Drug Des. Dev. Ther.* 2016, 10, 571–583.

214. Galoian, K.; Guettouche, T.; Issac, B.; Navarro, L.; Temple, H.T. Lost miRNA surveillance of notch, igfr pathway—Road to sarcomagenesis. *Tumour Biol.* 2014, 35, 483–492. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).